[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 97 of about 97
1. Wu C, Wei Q, Utomo V, Nadesan P, Whetstone H, Kandel R, Wunder JS, Alman BA: Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res; 2007 Sep 1;67(17):8216-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Side population cells isolated from mesenchymal neoplasms have tumor initiating potential.
  • Although many cancers are maintained by tumor-initiating cells, this has not been shown for mesenchymal tumors, in part due to the lack of unique surface markers that identify mesenchymal progenitors.
  • We examined 29 mesenchymal tumors ranging from benign to high-grade sarcomas and identified SP cells in all but six samples.
  • There was a positive correlation between the percentage of SP cells and the grade of the tumor.
  • SP cells preferentially formed tumors when grafted into immunodeficient mice, and only cells from tumors that developed from the SP cells had the ability to initiate tumor formation upon serial transplantation.
  • Although SP cells are able to efflux rhodamine dye in addition to Hoechst 33342, we found that the ability to efflux rhodamine dye did not identify a population of cells enriched for tumor-initiating capacity.
  • Here, we identify a subpopulation of cells within a broad range of benign and malignant mesenchymal tumors with tumor-initiating capacity.
  • [MeSH-major] Neoplasms, Connective and Soft Tissue / pathology. Neoplastic Stem Cells / cytology
  • [MeSH-minor] Animals. Cell Proliferation. Disease Progression. Humans. Mice. Mice, Inbred NOD. Mice, SCID. Neoplasm Invasiveness. Neoplasm Transplantation / pathology. Transplantation, Heterologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17804735.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


2. Yu Y, Fuhr J, Boye E, Gyorffy S, Soker S, Atala A, Mulliken JB, Bischoff J: Mesenchymal stem cells and adipogenesis in hemangioma involution. Stem Cells; 2006 Jun;24(6):1605-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesenchymal stem cells and adipogenesis in hemangioma involution.
  • Hemangioma is a benign tumor of infancy whose hallmark is rapid growth during the first year of life followed by slow regression during early childhood.
  • The proliferating phase is characterized by abundant immature endothelial cells, the involuting phase by prominent endothelial-lined vascular channels and endothelial apoptosis, and the involuted phase by few remaining capillary-like vessels surrounded by loose fibrofatty tissue.
  • We postulated that mesenchymal stem cells (MSCs) reside in the tumor and preferentially differentiate into adipocytes.
  • These hemangioma-derived MSCs (Hem-MSCs) are similar to MSCs obtained from human bone marrow, expressing the cell surface markers SH2 (CD105), SH3, SH4, CD90, CD29, smooth muscle alpha-actin, and CD133 but not the hematopoietic markers CD45 and CD14 or the hematopoietic/endothelial markers CD34, CD31, and kinase insert domain receptor (KDR).
  • [MeSH-major] Adipogenesis. Hemangioma / pathology. Mesenchymal Stromal Cells / pathology
  • [MeSH-minor] Antigens, Neoplasm / metabolism. Cell Differentiation. Cell Proliferation. Clone Cells / pathology. Female. Granuloma, Pyogenic / genetics. Granuloma, Pyogenic / immunology. Granuloma, Pyogenic / pathology. Humans. Infant. Infant, Newborn. Neoplasm Regression, Spontaneous / pathology. Neoplastic Stem Cells / pathology. Skin Neoplasms / genetics. Skin Neoplasms / immunology. Skin Neoplasms / pathology. X Chromosome Inactivation

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16456130.001).
  • [ISSN] 1066-5099
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / P01 AR 048564
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  •  go-up   go-down


3. Cai Z, Zhou Y, Lei T, Chiu JF, He QY: Mammary serine protease inhibitor inhibits epithelial growth factor-induced epithelial-mesenchymal transition of esophageal carcinoma cells. Cancer; 2009 Jan 1;115(1):36-48

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammary serine protease inhibitor inhibits epithelial growth factor-induced epithelial-mesenchymal transition of esophageal carcinoma cells.
  • BACKGROUND: By using proteomic technology, the authors previously observed the substantial down-regulation of mammary serine protease inhibitor (maspin) in esophageal squamous cell carcinoma and metastases.
  • In the current study, they examined the effects of maspin re-expression in a maspin-null esophageal cancer cell line EC109 and also investigated the underlying mechanism.
  • METHODS: A cell line with stable maspin expression was established.
  • An epithelial growth factor (EGF)-induced epithelial-mesenchymal transition (EMT) model was used to mimic some aspects of the metastatic process in vitro.
  • The effects of maspin reintroduction on EGF-induced EMT and cell growth characteristics were evaluated.
  • RESULTS: The introduction of maspin into EC109 cells was able to inhibit EGF-induced EMT and altered cell growth characteristics, including the serum dependence, proliferative response to EGF stimulation, and colony formation ability in soft agar, indicating a conversion from a malignant phenotype to a benign phenotype.
  • This finding provides additional evidence of the tumor metastasis-suppressive activity of maspin and may indicate a new direction for future studies of the mechanism of maspin.
  • [MeSH-minor] Cell Differentiation. Cell Line, Tumor. Epidermal Growth Factor / pharmacology. Epithelial Cells. Esophageal Neoplasms. Humans. Neoplasm Metastasis / prevention & control. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • (PMID = 19090015.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serine Proteinase Inhibitors; 0 / Serpins; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


Advertisement
4. Do TV, Kubba LA, Du H, Sturgis CD, Woodruff TK: Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition. Mol Cancer Res; 2008 May;6(5):695-705
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition.
  • Transforming growth factor-beta (TGF-beta) is thought to play a role in the pathobiological progression of ovarian cancer because this peptide hormone is overexpressed in cancer tissue, plasma, and peritoneal fluid.
  • In the current study, we investigated the role of the TGF-beta/Smad3 pathway in ovarian cancer metastasis by regulation of an epithelial-to-mesenchymal transition.
  • When cancer cells were cultured on plastic, TGF-beta1, TGF-beta2, and TGF-beta3 induced pro-matrix metalloproteinase (MMP) secretion, loss of cell-cell junctions, down-regulation of E-cadherin, up-regulation of N-cadherin, and acquisition of a fibroblastoid phenotype, consistent with an epithelial-to-mesenchymal transition.
  • Analysis of Smad3 nuclear expression in microarrays of serous benign tumors, borderline tumors, and cystadenocarcinoma revealed that Smad3 expression could be used to distinguish benign and borderline tumors from carcinoma (P = 0.006).
  • Furthermore, a direct relationship exists between Smad3 nuclear expression and expression of the mesenchymal marker N-cadherin in cancer patients (P = 0.0057).


5. Tjandra SS, Hsu C, Goh YI, Gurung A, Poon R, Nadesan P, Alman BA: IFN-{beta} signaling positively regulates tumorigenesis in aggressive fibromatosis, potentially by modulating mesenchymal progenitors. Cancer Res; 2007 Aug 1;67(15):7124-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IFN-{beta} signaling positively regulates tumorigenesis in aggressive fibromatosis, potentially by modulating mesenchymal progenitors.
  • Aggressive fibromatosis (also called desmoid tumor) is a benign, locally invasive, soft tissue tumor composed of cells with mesenchymal characteristics.
  • These tumors are characterized by increased levels of beta-catenin-mediated T-cell factor (TCF)-dependent transcriptional activation.
  • When mice deficient for the type 1 IFN receptor (Ifnar1-/-) were crossed with mice predisposed to developing aggressive fibromatosis tumors (Apc/Apc1638N), a significant decrease in aggressive fibromatosis tumor formation was observed compared with littermate controls, showing a novel role for type 1 IFN signaling in promoting tumor formation.
  • Type 1 IFN activation inhibits cell proliferation but does not alter cell apoptosis or the level of beta-catenin-mediated TCF-dependent transcriptional activation in aggressive fibromatosis cell cultures.
  • Intriguingly, Ifnar1-/- mice have smaller numbers of mesenchymal progenitor cells compared with littermate controls, and treatment of aggressive fibromatosis cell cultures with IFN increases the proportion of cells that exclude Hoechst dye and sort to the side population, raising the possibility that type 1 IFN signaling regulates the number of precursor cells present that drive aggressive fibromatosis tumor formation and maintenance.
  • This study identified a novel role for IFN type 1 signaling as a positive regulator of neoplasia and suggests that IFN treatment is a less than optimal therapy for this tumor type.
  • [MeSH-minor] Animals. Blotting, Western. Cell Proliferation. Cell Transformation, Neoplastic. Colony-Forming Units Assay. Female. Fibroblasts / metabolism. Flow Cytometry. Humans. Male. Mesenchymal Stromal Cells. Mice. Neoplasm Invasiveness / pathology. T Cell Transcription Factor 1 / metabolism. Transcription, Genetic. Transgenes / physiology. Tumor Cells, Cultured. beta Catenin / metabolism

  • Genetic Alliance. consumer health - Aggressive Fibromatosis.
  • Genetic Alliance. consumer health - Fibromatosis.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Res. 2008 Feb 1;68(3):956. Goh, Ingrid [corrected to Goh, Y Ingrid]
  • (PMID = 17671179.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, mouse; 0 / IFNAR1 protein, human; 0 / Ifnar1 protein, mouse; 0 / T Cell Transcription Factor 1; 0 / beta Catenin; 156986-95-7 / Receptor, Interferon alpha-beta; 77238-31-4 / Interferon-beta
  •  go-up   go-down


6. Ansieau S, Caron de Fromentel C, Bastid J, Morel AP, Puisieux A: [Role of the epithelial-mesenchymal transition during tumor progression]. Bull Cancer; 2010 Jan;97(1):7-15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of the epithelial-mesenchymal transition during tumor progression].
  • [Transliterated title] Rôle de la transition épithéliomésenchymateuse dans la progression tumorale.
  • The epithelial-mesenchymal transition (EMT) is a morphogenetic program that converts epithelial into mesenchymal cells during the embryonic development.
  • This mechanism is frequently reactivated during tumor progression and provides cells with motility and invasive capabilities favoring the metastatic dissemination from epithelial tumors.
  • Various EMT-inducing transcription factors, such as the TWIST proteins, were also shown to inhibit oncogene-induced fail-safe programs (senescence and apoptosis), thereby promoting the progression from benign to malignant stages.
  • Altogether, these observations suggest that EMT could play an important role in favoring both tumor development and metastatic dissemination.
  • [MeSH-major] Cell Transdifferentiation / physiology. Epithelial Cells / pathology. Mesoderm / pathology. Neoplasm Metastasis / pathology
  • [MeSH-minor] Animals. Cell Aging / physiology. Cell Movement / physiology. Disease Progression. Humans. Mice. Neoplasm Invasiveness. Neoplastic Stem Cells / physiology. Signal Transduction / physiology. Transcription Factors / physiology. Transcriptional Activation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026450.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Transcription Factors
  •  go-up   go-down


7. Cates JM, Byrd RH, Fohn LE, Tatsas AD, Washington MK, Black CC: Epithelial-mesenchymal transition markers in pancreatic ductal adenocarcinoma. Pancreas; 2009 Jan;38(1):e1-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial-mesenchymal transition markers in pancreatic ductal adenocarcinoma.
  • OBJECTIVES: Expression of transcription factors that mediate epithelial-mesenchymal transition (EMT), such as Twist and Slug, is correlated with poor prognosis in many tumor types.
  • Selected EMT markers were studied in a series of pancreatic ductal adenocarcinomas (PDAs) and benign pancreatic tissues to determine whether expression levels correlated with diagnosis, histologic grade, or patient outcome.
  • METHODS: Immunohistochemical stains for Twist, Slug, and N-cadherin were performed using a tissue microarray containing 68 PDAs and 38 samples of normal pancreas or chronic pancreatitis tissues.
  • RESULTS: Twist and Slug were identified in both the nucleus and cytoplasm of benign pancreatic ductal epithelium, chronic pancreatitis, and PDA.
  • Epithelial-mesenchymal transition marker expression was not associated with N-cadherin expression, patient outcome, or duration of survival.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 May;16(3):251-62 [18301244.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):598-606 [17258791.001]
  • [Cites] J Pathol. 2007 Apr;211(5):507-15 [17299729.001]
  • [Cites] Histopathology. 2007 Apr;50(5):648-58 [17394502.001]
  • [Cites] J Clin Pathol. 2007 May;60(5):510-4 [16822877.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jul 6;358(3):925-30 [17512904.001]
  • [Cites] Pathology. 2007 Jun;39(3):305-18 [17558857.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):816-29 [17243120.001]
  • [Cites] J Surg Res. 2007 Aug;141(2):196-203 [17583745.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):303-10 [17674958.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4769-76 [17699854.001]
  • [Cites] Gene. 2000 Oct 17;257(1):1-12 [11054563.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1613-8 [11912130.001]
  • [Cites] Oncogene. 2002 May 9;21(20):3241-6 [12082640.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1881-91 [12414534.001]
  • [Cites] Int J Oncol. 2003 Apr;22(4):891-8 [12632084.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):740-6 [14644200.001]
  • [Cites] J Histochem Cytochem. 2004 Jul;52(7):959-65 [15208362.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4125-33 [15217949.001]
  • [Cites] J Natl Cancer Inst. 1993 Feb 3;85(3):200-6 [8423624.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):188-95 [15644775.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1174-80 [15709186.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):155-65 [15790452.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1631-43 [15742334.001]
  • [Cites] Ann Surg Oncol. 2005 Jun;12(6):488-96 [15864483.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5153-62 [15958559.001]
  • [Cites] Development. 2005 Jul;132(14):3151-61 [15983400.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4524-31 [16002843.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):5991-5; discussion 5995 [16024595.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):5996-6000; discussion 6000-1 [16024596.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):197-209 [16169465.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8070-8 [16299238.001]
  • [Cites] Hum Pathol. 2006 Apr;37(4):431-8 [16564917.001]
  • [Cites] J Cell Biol. 2006 Mar 27;172(7):973-81 [16567498.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3365-9 [16585154.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1816-22 [16773075.001]
  • [Cites] J Biol Chem. 2006 Jul 28;281(30):21321-31 [16707493.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):314-20 [17211477.001]
  • [Cites] Int J Cancer. 2007 Apr 15;120(8):1634-40 [17236203.001]
  • (PMID = 18766116.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA095103; United States / NCI NIH HHS / CA / P50 CA095103-10; United States / NCI NIH HHS / CA / P50 CA95103
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CDH2 protein, human; 0 / Cadherins; 0 / Nuclear Proteins; 0 / TWIST1 protein, human; 0 / Transcription Factors; 0 / Twist Transcription Factor; 0 / snail family transcription factors
  • [Other-IDs] NLM/ NIHMS205920; NLM/ PMC2882851
  •  go-up   go-down


8. Weber KL, Peabody T, Frassica FJ, Mott MP, Parsons TW 3rd: Tumors for the general orthopedist: how to save your patients and practice. Instr Course Lect; 2010;59:579-91
MedlinePlus Health Information. consumer health - Joint Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is likely that most orthopaedic surgeons will see a patient with a benign or malignant musculoskeletal tumor sometime during their career.
  • However, because of the rarity of these entities, many surgeons may benefit from a review of how to evaluate a patient with a bone lesion or soft-tissue mass.
  • A logical approach is necessary in evaluating imaging studies as well as in the workup of children and adults with a possible tumor.
  • If the treatment algorithms lead to a conclusive diagnosis of a benign bone tumor, benign soft-tissue mass, or metastatic bone disease, the orthopaedic surgeon may choose to definitively treat the patient.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / surgery. Cysts / diagnosis. Joint Diseases / pathology. Orthopedics. Soft Tissue Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20415407.001).
  • [ISSN] 0065-6895
  • [Journal-full-title] Instructional course lectures
  • [ISO-abbreviation] Instr Course Lect
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Räsänen K, Vaheri A: TGF-beta1 causes epithelial-mesenchymal transition in HaCaT derivatives, but induces expression of COX-2 and migration only in benign, not in malignant keratinocytes. J Dermatol Sci; 2010 May;58(2):97-104
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TGF-beta1 causes epithelial-mesenchymal transition in HaCaT derivatives, but induces expression of COX-2 and migration only in benign, not in malignant keratinocytes.
  • BACKGROUND: Transforming growth factor beta (TGF-beta) acts as a tumor promoter by inducing epithelial-mesenchymal transition (EMT), which leads to a motile phenotype, enabling invasion and metastasis of cancer cells.
  • Cancer-related inflammation, mediated by prostaglandins, has been proposed as a critical mechanism in conversion of benign cells to malignant.
  • OBJECTIVE: Induction of cyclooxygenase 2 (COX-2), producer of prostaglandins, is thought to be a prerequisite for TGF-beta-induced EMT in benign cells.
  • METHODS: Effect of TGF-beta1 was investigated by analyzing cell proliferation, morphology and protein expression.
  • RESULTS: TGF-beta1 caused proliferation arrest of benign and malignant HaCaT cells, and changed the epithelial morphology of benign and low-grade malignant cells, but not metastatic cells, to mesenchymal spindle-shape.
  • Epithelial junction proteins ZO-1 and E-cadherin were downregulated in all cell lines in response to TGF-beta1, but mesenchymal markers were not induced, suggesting a partial EMT response.
  • COX-2 and migration were induced only in benign HaCaT derivatives.
  • Malignant derivatives did not induce COX-2 in response to TGF-beta 1 treatment, thus emphasizing the role of inflammation in EMT response of benign cells.
  • CONCLUSIONS: TGF-beta1 operates via distinct mechanisms in inducing EMT and metastasis, and supporting this we show that TGF-beta1 induces COX-2 and promotes the migration of benign cells, but does not further augment the migration of malignant cells, indicating their resistance to TGF-beta1 in the context of motility.
  • [MeSH-minor] Cell Line, Tumor. Cell Movement. Cell Proliferation. Chemotaxis. Humans. Immunohistochemistry / methods. Models, Biological. Neoplasm Metastasis. Transforming Growth Factor beta / metabolism. Wound Healing

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20399617.001).
  • [ISSN] 1873-569X
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


10. Miettinen M, Makhlouf HR, Sobin LH, Lasota J: Plexiform fibromyxoma: a distinctive benign gastric antral neoplasm not to be confused with a myxoid GIST. Am J Surg Pathol; 2009 Nov;33(11):1624-32
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plexiform fibromyxoma: a distinctive benign gastric antral neoplasm not to be confused with a myxoid GIST.
  • A great majority of gastric mesenchymal tumors are gastrointestinal stromal tumor (GIST).
  • A rare group of non-GISTs include myxoid mesenchymal neoplasms.
  • In this report, we describe 12 cases of a distinctive gastric tumor, named here as plexiform fibromyxoma.
  • All tumors were located in the gastric antrum and 6 of them also extended into extragastric soft tissues or into the duodenal bulb.
  • Extramural components included subserosal nodules, and sometimes more cellular, solid nonplexiform spindle cell proliferation.
  • The tumor cells varied from oval to spindled and had limited atypia and mitotic activity < 5/50 high-power fields.
  • Immunohistochemically, the tumor cells were positive for alpha smooth muscle actin, and variably for CD10, and were consistently negative for KIT, DOG1, CD34, desmin, and S100 protein.
  • Additional 3 patients survived 14 to 25 years with unknown tumor status.
  • Review of large numbers of mesenchymal tumors in the esophagus and intestines did not reveal similar tumors.
  • Plexiform fibromyxoma is a distinctive benign gastric antral neoplasm that should be separated from GIST, nerve sheath tumors, and other fibromyxoid neoplasms.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Child. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Young Adult

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19675452.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


11. Ahrens WA, Ridenour RV 3rd, Caron BL, Miller DV, Folpe AL: GLUT-1 expression in mesenchymal tumors: an immunohistochemical study of 247 soft tissue and bone neoplasms. Hum Pathol; 2008 Oct;39(10):1519-26
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GLUT-1 expression in mesenchymal tumors: an immunohistochemical study of 247 soft tissue and bone neoplasms.
  • However, GLUT-1 expression has not been systematically examined in other mesenchymal neoplasms.
  • Prompted by a recent report of GLUT-1 expression in epithelioid sarcoma, a tumor not generally felt to show perineurial differentiation, we examined GLUT-1 expression in a wide variety of mesenchymal tumors.
  • Sections from 247 mesenchymal tumors of a variety of histologic subtypes were retrieved from our archives and immunostained for GLUT-1 using heat-induced epitope retrieval and the DAKO ADVANCE detection system (DAKO, Carpinteria, CA).
  • All benign nerve sheath tumors showed a peripheral rim of positive normal perineurial cells, with 2 neurofibromas and 3 schwannomas showing more extensive staining.
  • GLUT-1 expression was also seen in a wide variety of benign and malignant mesenchymal tumors.
  • We conclude that GLUT-1 expression in mesenchymal tumors is by no means specific for perineurial differentiation, but may instead represent upregulation of this protein within hypoxic zones, secondary to upstream activation of proteins such as hypoxia-inducible factor 1-alpha.
  • [MeSH-major] Bone Neoplasms / metabolism. Glucose Transporter Type 1 / metabolism. Mesenchymoma / metabolism. Soft Tissue Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Count. Humans. Immunohistochemistry. Neoplasm Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18620729.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / Neoplasm Proteins
  •  go-up   go-down


12. Lin TM, Chang HW, Wang KH, Kao AP, Chang CC, Wen CH, Lai CS, Lin SD: Isolation and identification of mesenchymal stem cells from human lipoma tissue. Biochem Biophys Res Commun; 2007 Oct 5;361(4):883-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation and identification of mesenchymal stem cells from human lipoma tissue.
  • Lipoma is a benign neoplasm of normal fat cells that appears as a soft, movable swelling, often with a slight yellowish coloration.
  • Human mesenchymal stem cells (MSCs) that have been isolated from bone marrow, blood, and other adult tissues including adipose tissue have the potential to be useful candidates for therapy.
  • No literature had reported about stem cells from lipoma tissue.
  • Here, a new cell culture method is described and utilized to greatly accelerate the growth rate and prolong the lifespan of lipoma-derived MSCs.
  • Cells produced in early cultures display characteristics similar to those previously reported for multipotential stem cells, including a high frequency of anchorage-independent growth in soft agar and a lack of gap junctional intercellular communication in cell types with serpiginous morphology.
  • [MeSH-major] Lipoma / pathology. Mesenchymal Stromal Cells / cytology
  • [MeSH-minor] Adipogenesis. Cell Culture Techniques. Cell Division. Cell Lineage. Cell Proliferation. Chondrogenesis. Gap Junctions / metabolism. Humans. Immunophenotyping. Osteogenesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679141.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Joyner DE, Damron TA, Aboulafia A, Bokor W, Bastar JD, Randall RL: Heterogeneous expression of melanoma antigen (hMAGE) mRNA in mesenchymal neoplasia. Tissue Antigens; 2006 Jul;68(1):19-27
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneous expression of melanoma antigen (hMAGE) mRNA in mesenchymal neoplasia.
  • At present, little information is available regarding CT expression in mesenchymal neoplasms, and it remains uncertain whether CT immunotherapy will serve as a viable alternative or adjunct to current sarcoma therapies involving resection, followed by adjuvant radiotherapy and/or chemotherapy.
  • In this study, hMAGEA2, hMAGEA3, hMAGEA4, and hMAGEC1 mRNA content in 21 benign mesenchymal tumors (representing seven histotypes) and 28 primary sarcomas (10 histotypes) was inventoried using real-time-PCR and then compared against hMAGE mRNA expression in non-sarcomatous malignancies, three cell lines, and muscle. hMAGEA2, hMAGEA3, and hMAGEC1 transcripts were infrequent in mesenchymal tissues in general, whereas hMAGEA4 mRNA was present in 84% of all mesenchymal tumors, 100% of non-sarcomatous tumors, all three cell lines, and in four of five muscle samples.
  • The presence of hMAGEA4 mRNA in muscle, plus the inconsistent and infrequent occurrence of hMAGEA2, hMAGEA3, and hMAGEC1 mRNA within and among mesenchymal tumor histotypes, makes these four hMAGE antigens unlikely candidates for sarcoma-specific immunotherapy.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Neoplasm Proteins / metabolism. Neoplasms / metabolism. Neoplasms, Connective Tissue / metabolism. Sarcoma / metabolism. Testis / immunology
  • [MeSH-minor] Cell Line. Cell Line, Tumor. Gene Expression. Humans. Male. Melanoma-Specific Antigens. Muscle, Skeletal / metabolism. Neoplasm Metastasis / pathology. RNA, Messenger / metabolism. RNA, Neoplasm / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Tissue Antigens. 2006 Aug;68(2):192
  • (PMID = 16774536.001).
  • [ISSN] 0001-2815
  • [Journal-full-title] Tissue antigens
  • [ISO-abbreviation] Tissue Antigens
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MAGEA1 protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


14. Yamamoto T: Dermatofibroma: a possible model of local fibrosis with epithelial/mesenchymal cell interaction. J Eur Acad Dermatol Venereol; 2009 Apr;23(4):371-5
Genetic Alliance. consumer health - Dermatofibroma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatofibroma: a possible model of local fibrosis with epithelial/mesenchymal cell interaction.
  • Dermatofibromas are benign dermal nodules usually seen on the extremities; however, whether a dermatofibroma is a reactive fibrous hyperplasia or a true neoplasm is still unclear.
  • Interaction between proliferated dermatofibroma fibroblasts and overlying elongated epidermis suggests a relationship between keratinocytes and mesenchymal cells.
  • [MeSH-major] Epithelial Cells / pathology. Fibrosis / pathology. Histiocytoma, Benign Fibrous / pathology. Mesoderm / pathology. Models, Biological

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19175704.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 54
  •  go-up   go-down


15. Michal M, Kazakov DV, Síma R, Vanecek T: Primitive small cell tumor with epithelial, gangliocytic, neuroendocrine, and mesenchymal differentiation: report of 2 cases. Int J Surg Pathol; 2007 Oct;15(4):429-36
Genetic Alliance. consumer health - Pancreatic islet cell tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive small cell tumor with epithelial, gangliocytic, neuroendocrine, and mesenchymal differentiation: report of 2 cases.
  • The predominant cell type was small round to fusiform dark blue cells.
  • Another distinctive component of the tumors was a mesenchymal one.
  • The mesenchymal areas appeared benign and could be likened to a fibroma having a densely collagenous stroma, or they had spindle cells set in the myxoid background, rendering a myxoma-like appearance.
  • Another distinctive feature was ganglion cell differentiation.
  • Mitotic figures, including atypical forms, were found only in the small cell component.
  • We suggest the name "primitive small cell tumor with epithelial, gangliocytic, neuroendocrine, and mesenchymal differentiation" for this neoplasm.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Neuroendocrine Tumors / pathology. Sarcoma, Small Cell / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Aneuploidy. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic. Child, Preschool. Chromosomes, Human, Pair 12. Combined Modality Therapy. Desmosomes / ultrastructure. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Microscopy, Electron, Transmission. Secretory Vesicles / ultrastructure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17913955.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


16. Agaimy A, Wuensch PH: Perineurioma of the stomach. A rare spindle cell neoplasm that should be distinguished from gastrointestinal stromal tumor. Pathol Res Pract; 2005;201(6):463-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perineurioma of the stomach. A rare spindle cell neoplasm that should be distinguished from gastrointestinal stromal tumor.
  • We report on the first case of benign perineurially differentiated peripheral nerve sheath tumor (perineurioma) presenting as a bleeding gastric mass in a 30-year-old, previously healthy woman with no signs or stigmata of von Recklinghausen's disease or other primary tumor at time of presentation.
  • Gastric resection specimen revealed an ulcerated moderately cellular mesenchymal tumor consisting of elongated wavy spindle cells arranged in a fascicular and sheet-like pattern with focal whorling and occasional alternation of dark staining cellular and light staining hypocellular areas.
  • Tumor cells were strongly immunoreactive for epithelial membrane antigen, CD56 (N-CAM), and vimentin, but were negative for S-100-protein and other lineage-specific epithelial, mesenchymal, hematolymphoid, and reticulo-histiocytic markers.
  • We presume that the combined histological and immunohistochemical profiles of this unusual gastric neoplasm are consistent with a diagnosis of perineurioma with a probably benign biological behavior.
  • To our knowledge, this is the first report of gastric perineurioma, an extremely rare mesenchymal lesion that should be considered among the differential diagnoses of gastrointestinal stromal tumor, especially the so-called KIT-negative GIST.
  • Gastrointestinal perineuriomas might be under-recognized, as our case was initially diagnosed as a benign GIST.
  • [MeSH-minor] Adult. Antigens, CD56 / metabolism. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Mucin-1 / metabolism. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16136753.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Biomarkers, Tumor; 0 / Mucin-1
  •  go-up   go-down


17. Mentzel T, Toennissen J, Rütten A, Schaller J: Palmar atypical lipomatous tumour with spindle cell features (well-differentiated spindle cell liposarcoma): a rare neoplasm arising in an unusual anatomical location. Virchows Arch; 2005 Mar;446(3):300-4
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palmar atypical lipomatous tumour with spindle cell features (well-differentiated spindle cell liposarcoma): a rare neoplasm arising in an unusual anatomical location.
  • Lipomatous tumours, both benign and malignant, arising on the hands are uncommon.
  • We present a rare atypical lipomatous tumour with spindle cell features (synonym: well-differentiated spindle cell liposarcoma) arising on the left palm of a 54-year-old male patient.
  • The neoplasm presented as a long-standing, exophytic neoplasm measuring 9 x 9 cm.
  • The well-circumscribed neoplasm was completely excised, and margins were tumour free.
  • Histologically, the neoplasm showed features closely resembling spindle cell lipoma, being composed of mature adipocytic cells associated with bland, neuroid spindle cells staining positively for CD34.
  • Aypical lipomatous tumour with spindle cell features may arise very rarely in palmar location and has to be distinguished from a number of benign and malignant mesenchymal neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1995;427(4):353-63 [8548119.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1192-9 [11106076.001]
  • [Cites] Am J Dermatopathol. 2000 Dec;22(6):496-502 [11190440.001]
  • [Cites] Cancer. 1975 Nov;36(5):1852-9 [1192370.001]
  • [Cites] Am J Clin Oncol. 2001 Feb;24(1):81-4 [11232956.001]
  • [Cites] Am Surg. 1975 Feb;41(2):117-20 [1122062.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):126-33 [7459800.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jan;24(1):30-41 [9892106.001]
  • [Cites] Scand J Plast Reconstr Surg Hand Surg. 2000 Jun;34(2):185-7 [10900638.001]
  • [Cites] Ann Diagn Pathol. 2001 Oct;5(5):255-66 [11598853.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1182-9 [8827023.001]
  • [Cites] Acta Orthop Belg. 1994;60(3):334-5 [7992615.001]
  • [Cites] J Bone Joint Surg Am. 1994 Sep;76(9):1360-2 [8077265.001]
  • [Cites] Ann Diagn Pathol. 2000 Dec;4(6):354-60 [11149965.001]
  • [Cites] Gan No Rinsho. 1989 Feb;35(3):437-41 [2926990.001]
  • [Cites] J Hand Surg Am. 1989 Jul;14(4):700-4 [2754203.001]
  • [Cites] Ann Diagn Pathol. 2002 Apr;6(2):83-93 [12004355.001]
  • [Cites] Am J Surg Pathol. 1994 Sep;18(9):913-21 [8067512.001]
  • [Cites] Ann Plast Surg. 1983 Nov;11(5):431-3 [6651174.001]
  • [Cites] Cutis. 1987 Jul;40(1):29-32 [3665587.001]
  • [Cites] J Bone Joint Surg Am. 1965 Jun;47:727-40 [14299665.001]
  • (PMID = 15719245.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Gos M, Miłoszewska J, Przybyszewska M: [Epithelial-mesenchymal transition in cancer progression]. Postepy Biochem; 2009;55(2):121-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epithelial-mesenchymal transition in cancer progression].
  • According to recently published data, the epithelial-mesenchymal transition--a process important for embryonic development, may be involved in many pathological processes such as wound healing, tissue fibrosis or cancer progression.
  • The EMT process in cell is driven by growth factors (EGF, PDGF, HGF) or other signaling proteins such as TGF-beta, sonic hedgehog (Shh), Wnt/beta-catenin and extracellular matrix (ECM) components that may stimulate cellular growth and migration.
  • During cancer progression, the EMT process is necessary to the conversion of benign tumor to aggressive and highly invasive cancer.
  • The loss of adhesion is accompanied by molecular and morphologic changes in cancer cells that are essential for the phenotypic change from epithelial to mesenchymal one, and the acquirement of higher migration and invasion potential.
  • During the colonization of distant sites, a reverse process mesenchymal-epithelial transition (MET) takes place and metastatic cancer cells again acquire the epithelial phenotype.
  • It has been suggested that also cells within tumor microenvironment e.g. cancer associated fibroblasts (CAF) are generated in part from normal epithelial cells in EMT process.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Epithelial Cells / pathology. Mesoderm / pathology. Neoplasms / pathology. Neoplasms / physiopathology
  • [MeSH-minor] Animals. Anoikis. Disease Progression. Humans. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Neoplasm Metastasis / pathology. Neoplasm Metastasis / physiopathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19824467.001).
  • [ISSN] 0032-5422
  • [Journal-full-title] Postepy biochemii
  • [ISO-abbreviation] Postepy Biochem.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 73
  •  go-up   go-down


19. Stringer MD, Alizai NK: Mesenchymal hamartoma of the liver: a systematic review. J Pediatr Surg; 2005 Nov;40(11):1681-90
MedlinePlus Health Information. consumer health - Prenatal Testing.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesenchymal hamartoma of the liver: a systematic review.
  • Mesenchymal hamartoma of the liver is the second commonest benign liver tumor in children, yet its biology and pathogenesis are poorly understood.
  • Cytogenetic studies have suggested that the tumor may be a neoplasm rather than a hamartoma.
  • Typically, it presents as a large benign multicystic liver mass in a child younger than 3 years amenable to complete resection.
  • In addition, the tumor occasionally contains angiomatous elements or is multifocal.
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Transformation, Neoplastic. Child. Child, Preschool. Embolization, Therapeutic. Female. Humans. Infant. Infant, Newborn. Male. Mesoderm. Middle Aged. Pregnancy. Prognosis. Remission, Spontaneous. Risk Factors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16291152.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 107
  •  go-up   go-down


20. Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Briaire-de Bruijn I, de Jong D, van Pel M, Cleton-Jansen AM, Hogendoorn PC: Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol; 2009 Nov;219(3):294-305
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2.
  • It lacks a benign precursor lesion and reports on associations with hereditary predisposition or germline mutations are uncommon, despite the early age of onset.
  • Here we demonstrate a novel comprehensive approach for the study of premalignant stages of osteosarcoma development in a murine mesenchymal stem cell (MSC) system that formed osteosarcomas upon grafting.
  • Moreover, occasional reports in patients mention osteosarcoma formation following bone marrow transplantation for an unrelated malignancy.
  • [MeSH-major] Bone Neoplasms / pathology. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Mesenchymal Stromal Cells / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Aneuploidy. Animals. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cell Differentiation. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Disease Models, Animal. Humans. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Mice, Nude. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Neoplasm Transplantation. Phenotype. Survival Analysis. Treatment Outcome. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19718709.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Neoplasm Proteins
  •  go-up   go-down


21. Joyner DE, Wade ML, Szabo A, Bastar J, Coffin CM, Albritton KH, Bernard PS, Randall RL: Discriminate gene lists derived from cDNA microarray profiles of limited samples permit distinguishing mesenchymal neoplasia ex vivo. J Cancer Res Clin Oncol; 2005 Mar;131(3):137-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discriminate gene lists derived from cDNA microarray profiles of limited samples permit distinguishing mesenchymal neoplasia ex vivo.
  • BACKGROUND: Mesenchymal neoplasia comprises a heterogeneous group of tumors with over 200 benign neoplasms and 100 sarcomas.
  • As a feasibility study, our goal was to generate a preliminary discriminatory gene list for selected mesenchymal tumors, including sarcomas.
  • This technique may enable an eventual molecular classification schema based on expression profiles that can complement current clinical and pathologic diagnostic procedures in mesenchymal tumors.
  • METHODS: cDNA microarray analyses were preformed on connective tissue tumors obtained at time of surgical resection or biopsy.
  • Messenger RNA (mRNA) from four general tumor classes was competitively hybridized against a human dermal fibroblast cell line comparator and the resulting gene expression profiles processed by ANOVA and linear discriminate analysis.
  • RESULTS: The tissue classification involved 18 patients with malignant peripheral nerve sheath tumors, giant cell containing tumors, benign spindle cell lesions, or Ewing's family of tumors.
  • Twenty-five differentially regulated genes considered most variable among the five tissue classes were identified.
  • CONCLUSIONS: Linear discriminate analysis of cDNA gene expression profiles partitioned mesenchymal tumor classes, even when constrained by limited sample sizes.
  • [MeSH-major] DNA Fingerprinting. DNA, Neoplasm / analysis. Mesenchymoma / diagnosis. Mesenchymoma / genetics. Neoplasms, Connective Tissue / diagnosis. Neoplasms, Connective Tissue / genetics. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Analysis of Variance. Carcinoma / diagnosis. Carcinoma / genetics. Carcinoma, Giant Cell / diagnosis. Carcinoma, Giant Cell / genetics. Cell Line. Feasibility Studies. Fibroblasts. Gene Expression Regulation, Neoplastic. Humans. Linear Models. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / genetics. RNA, Messenger / analysis. RNA, Neoplasm / analysis. Sarcoma, Ewing / diagnosis. Sarcoma, Ewing / genetics. Skin / cytology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1256-60 [11888886.001]
  • [Cites] Science. 1996 Aug 30;273(5279):1236-8 [8703060.001]
  • [Cites] Am J Clin Pathol. 2001 Oct;116(4):473-6 [11601130.001]
  • [Cites] Cell. 2000 Oct 13;103(2):211-25 [11057895.001]
  • [Cites] J Biol Chem. 1990 Feb 15;265(5):2665-70 [2406238.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1329-34 [11870176.001]
  • [Cites] Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S110-9 [14600600.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] Math Biosci. 2002 Mar;176(1):71-98 [11867085.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6649-55 [11559528.001]
  • [Cites] J Comput Biol. 2000;7(6):819-37 [11382364.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4776-81 [11156234.001]
  • [Cites] J Cell Physiol. 2003 May;195(2):309-21 [12652657.001]
  • [Cites] Cancer Control. 2001 May-Jun;8(3):239-51 [11378650.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3695-6 [10577840.001]
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:207-35 [14570569.001]
  • [Cites] Hum Mutat. 2000;16(1):18-22 [10874300.001]
  • [Cites] J Cell Biochem. 2000 Jun 12;78(4):627-37 [10861860.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):175-8 [12242149.001]
  • [Cites] FASEB J. 1999 May;13(8):781-92 [10224222.001]
  • [Cites] Nat Med. 2001 Jun;7(6):673-9 [11385503.001]
  • [Cites] Bioinformatics. 2003 Jan;19(1):53-61 [12499293.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5859-66 [12384549.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2281-6 [11956084.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):728-35 [8573349.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Annu Rev Cell Dev Biol. 2001;17:463-516 [11687497.001]
  • [Cites] Clin Orthop Relat Res. 2003 Oct;(415):59-63 [14612630.001]
  • [Cites] J Cell Physiol. 1999 May;179(2):170-8 [10199556.001]
  • [Cites] Oncogene. 1999 Mar 4;18(9):1771-6 [10208438.001]
  • [Cites] Oncogene. 1995 Apr 6;10(7):1461-3 [7731700.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3539-45 [12839939.001]
  • [Cites] J Cell Biol. 2000 Feb 21;148(4):779-90 [10684258.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1791-5 [11280724.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):91-101 [9665469.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5656-61 [10582678.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13085-9 [12351679.001]
  • [Cites] J Clin Oncol. 1983 Aug;1(8):496-509 [6366142.001]
  • (PMID = 15614524.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


22. Kondi-Pafiti A, Grapsa D, Kairi-Vassilatou E, Kontogianni-Katsarou K, Koliopoulos C, Botsis D: Mesenchymal tumors of the uterine corpus with heterologous and hematopoietic components: a study of ten cases and review of the literature. Eur J Gynaecol Oncol; 2006;27(1):73-7
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesenchymal tumors of the uterine corpus with heterologous and hematopoietic components: a study of ten cases and review of the literature.
  • OBJECTIVE: To study the histopathological features of mesenchymal tumors of the uterine corpus with heterologous and hematopoietic components, and review their histogenesis and differential diagnosis from other neoplastic and non-neoplastic lesions.
  • METHODS: Ten cases of mesenchymal tumors of the uterine corpus, massively infiltrated by hematopoioetic cells, or composed of other benign heterologous elements (adipose tissue in the present cases) were retrieved from the archival files of our laboratory and studied histopathologically.
  • RESULTS: Six of our studied cases were diagnosed as leiomyomas, two as lipoleiomyomas, one as a symplastic lipoleiomyoma, and one as an endometrial stromal tumor.
  • Immunohistochemical study of the leiomyomas with massive lymphocytic infiltration revealed the presence of a predominantly B-cell population within the infiltrate, which was polyclonal in nature.
  • The endometrial stromal tumor was severely infiltrated by histiocytes, and was positive for vimentin, CD10, PgR and negative for actin, desmin, ER and caldesmon.
  • CONCLUSION: The presence of hematopoietic or heterologous elements within an otherwise bland uterine leiomyoma or endometrial stromal tumor may give rise to diagnostic difficulties.
  • Regularity of the tumor margins, low mitotic activity and absence of nuclear atypia or necrosis should be established for the exclusion of a malignancy.
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Disease Progression. Female. Hematopoietic System / pathology. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Prognosis. Registries. Retrospective Studies. Risk Assessment

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550975.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 37
  •  go-up   go-down


23. Mukherjee S, Frolova N, Sadlonova A, Novak Z, Steg A, Page GP, Welch DR, Lobo-Ruppert SM, Ruppert JM, Johnson MR, Frost AR: Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther; 2006 Jun;5(6):674-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer.
  • The hedgehog pathway regulates epithelial-mesenchymal interactions, differentiation, proliferation and survival during development.
  • Stimulation of hedgehog signaling induces carcinogenesis or promotes cell survival in cancers of multiple organs.
  • Using real-time, quantitative PCR, laser capture microdissection, and immunohistochemistry, distinctive patterns of expression of the hedgehog pathway members patched 1 (PTCH1), smoothened, GLI1, GLI2 and the 3 hedgehog ligands were identified for epithelial cells and stromal fibroblasts in benign breast and breast cancer.
  • Hedgehog ligands were expressed at higher levels in some cancer epithelial cell lines compared to noncancerous epithelial cells.
  • Correspondingly, expression of GLI1, a transcription factor and transcriptional product of hedgehog signaling, was increased 8-fold in cancer epithelial cell lines; however, PTCH1, also a transcriptional target of hedgehog signaling in many cell types, was not increased.
  • Hedgehog-mediated transcription, as indicated by a reporter of GLI-dependent promoter activity and by expression of GLI1 transcripts, was reduced by the hedgehog pathway inhibitor cyclopamine in both MDA-MB-435 cancer epithelial cells and MCF10AT epithelial cells, a cell line derived from benign breast.
  • However, cyclopamine reduced viability of cancer epithelial cell lines, including MDA-MB-435, but did not specifically affect fibroblasts or epithelial cells from benign breast, including MCF10AT.
  • These results demonstrate modulation of GLI-mediated transcription in both cancer and benign-derived epithelial cells by cyclopamine and sonic hedgehog, and further suggest that hedgehog signaling contributes to the survival of only the cancer epithelial cells.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 2002 Apr;17(2):623-37 [11962762.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6 [16488983.001]
  • [Cites] Genes Dev. 2002 Nov 1;16(21):2743-8 [12414725.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):923-8 [12615704.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):508-13 [12652302.001]
  • [Cites] J Endocrinol. 2003 Sep;178(3):467-78 [12967338.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 6;314(2):313-20 [14733907.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] Biochem J. 2004 Mar 1;378(Pt 2):353-62 [14611647.001]
  • [Cites] J Agric Food Chem. 2004 May 19;52(10):2832-9 [15137822.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3479-85 [15150101.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):831-7 [15170664.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2577-85 [15277480.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):165-81 [15300011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]
  • [Cites] Development. 2004 Oct;131(20):5009-19 [15371305.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Int J Mol Med. 2004 Nov;14(5):793-9 [15492847.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Science. 1997 May 2;276(5313):817-21 [9115210.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):711-3 [10505029.001]
  • [Cites] Mol Cancer. 2004 Oct 13;3:29 [15482598.001]
  • [Cites] Breast Cancer Res. 2005;7(1):R46-59 [15642169.001]
  • [Cites] Development. 1999 Nov;126(22):5181-93 [10529434.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):236-43 [10981877.001]
  • [Cites] Nature. 2001 Feb 1;409(6820):633-7 [11214324.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1320-6 [11245428.001]
  • [Cites] J Invest Dermatol. 2001 Mar;116(3):472-4 [11231326.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):97-104 [11322829.001]
  • [Cites] Dev Biol. 2001 Oct 1;238(1):133-44 [11783999.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):118-27 [11857395.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]
  • [Cites] Histol Histopathol. 2002 Apr;17(2):599-621 [11962761.001]
  • [Cites] Dev Biol. 2005 Apr 1;280(1):111-21 [15766752.001]
  • [Cites] Genomics. 2005 Apr;85(4):462-71 [15780749.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):306-17 [15803137.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Development. 2005 Jul;132(14):3267-79 [15983404.001]
  • [Cites] J Neurosci. 2005 Sep 7;25(36):8338-46 [16148242.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1698-705 [15905200.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):139-48 [16003737.001]
  • [Cites] Hum Mol Genet. 2005 Nov 15;14(22):3379-88 [16203740.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):107-15 [12241103.001]
  • (PMID = 16855373.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA091421; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / R01 CA087728; United States / NCI NIH HHS / CA / R03 CA105950
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Hedgehog Proteins; 0 / RNA, Neoplasm; 0 / SHH protein, human; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ NIHMS11622; NLM/ PMC1557635
  •  go-up   go-down


24. Cordeiro SZ, Cordeiro Pde B, Sousa AM, Lannes DC, Pierro GS: Giant cell tumor of the rib occupying the entire hemithorax. J Bras Pneumol; 2008 Mar;34(3):185-8
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the rib occupying the entire hemithorax.
  • The authors report the case of a 28-year-old female patient with a giant cell tumor originating from the rib.
  • The tumor, measuring 25 x 17 cm, occupied the entire hemithorax and caused atelectasis of the left lung.
  • This tumor was a benign mesenchymal neoplasm, which rarely affects the ribs.
  • A thoracotomy involving en bloc resection of the chest wall and tumor was performed.
  • Despite the large dimensions of the tumor, complete resection was possible, and lung function was restored.
  • [MeSH-major] Bone Neoplasms / diagnosis. Giant Cell Tumor of Bone / diagnosis. Ribs

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392468.001).
  • [ISSN] 1806-3756
  • [Journal-full-title] Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • [ISO-abbreviation] J Bras Pneumol
  • [Language] eng; por
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


25. Lax S: [Mesenchymal uterine tumors. Stromal tumors and other rare mesenchymal neoplasms]. Pathologe; 2009 Jul;30(4):284-91
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mesenchymal uterine tumors. Stromal tumors and other rare mesenchymal neoplasms].
  • Adenosarcomas are mixed neoplasms with a low grade stromal sarcoma component containing benign glands, which are surrounded by condensed neoplastic stroma.
  • [MeSH-minor] Arterioles / pathology. Cell Differentiation. Cell Nucleus / pathology. Cytoplasm / pathology. Diagnosis, Differential. Female. Humans. Muscle, Skeletal / pathology. Muscle, Smooth / pathology. Neoplasm Invasiveness. Neoplasm Metastasis. Sarcoma / pathology. Sex Cord-Gonadal Stromal Tumors / pathology. Uterus / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2007 Oct;60(10):1148-54 [17182656.001]
  • [Cites] Am J Clin Pathol. 1976 Sep;66(3):512-25 [961630.001]
  • [Cites] J Mol Diagn. 2005 Aug;7(3):388-95 [16049311.001]
  • [Cites] Virchows Arch. 2004 May;444(5):410-4 [15007645.001]
  • [Cites] Am J Surg Pathol. 1995 Jul;19(7):757-68 [7793473.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):229-35 [18317219.001]
  • [Cites] Histopathology. 1981 Jan;5(1):1-10 [7216172.001]
  • [Cites] Adv Anat Pathol. 2004 May;11(3):162-71 [15096730.001]
  • [Cites] J Clin Pathol. 2007 Mar;60(3):235-43 [17347285.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1228-38 [18580489.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):997-1005 [9706980.001]
  • [Cites] Histopathology. 2009 Feb;54(3):355-64 [19236512.001]
  • [Cites] Int J Gynaecol Obstet. 2009 Mar;104(3):177-8 [19135669.001]
  • [Cites] Adv Anat Pathol. 2004 Nov;11(6):310-5 [15505532.001]
  • [Cites] Int J Gynecol Cancer. 2005 Mar-Apr;15(2):337-42 [15823122.001]
  • [Cites] Pathology. 2007 Feb;39(1):46-54 [17365822.001]
  • [Cites] Am J Surg Pathol. 2009 Feb;33(2):278-88 [18941402.001]
  • (PMID = 19495764.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Veveris-Lowe TL, Lawrence MG, Collard RL, Bui L, Herington AC, Nicol DL, Clements JA: Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr Relat Cancer; 2005 Sep;12(3):631-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.
  • In this study, we now show that the comparative expression of hK4 protein in prostate cancer tissues, compared with benign glands, is greater than that of PSA and kallikrein 2 (KLK2/hK2), suggesting that hK4 may play an important functional role in prostate cancer progression in addition to its biomarker potential.
  • To examine the roles that hK4, as well as PSA and hK2, play in processes associated with progression, these kallikreins were separately transfected into the PC-3 prostate cancer cell line, and the consequence of their stable transfection was investigated.
  • PC-3 cells expressing hK4 had a decreased growth rate, but no changes in cell proliferation were observed in the cells expressing PSA or hK2. hK4 and PSA, but not hK2, induced a 2.4-fold and 1.7-fold respective increase, in cellular migration, but not invasion, through Matrigel, a synthetic extracellular matrix.
  • We hypothesised that this increase in motility displayed by the hK4 and PSA-expressing PC-3 cells may be related to the observed change in structure in these cells from a typical rounded epithelial-like cell to a spindle-shaped, more mesenchymal-like cell, with compromised adhesion to the culture surface.
  • Thus, the expression of E-cadherin and vimentin, both associated with an epithelial-mesenchymal transition (EMT), was investigated.
  • The loss of E-cadherin and associated increase in vimentin are indicative of EMT and provides compelling evidence that hK4, in particular, and PSA have a functional role in the progression of prostate cancer through their promotion of tumour cell migration.
  • [MeSH-minor] Cell Division. Cell Line, Tumor. Cell Movement. Epithelial Cells / pathology. Humans. Male. Mesoderm / pathology. Neoplasm Invasiveness


27. Hameed M, Clarke K, Amer HZ, Mahmet K, Aisner S: Cellular angiofibroma is genetically similar to spindle cell lipoma: a case report. Cancer Genet Cytogenet; 2007 Sep;177(2):131-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular angiofibroma is genetically similar to spindle cell lipoma: a case report.
  • Cellular angiofibroma is a benign mesenchymal neoplasm of female and male genital tract composed of prominent vasculature and stromal spindle cells, often with admixture of adipose tissue.
  • The tumor has histomorphologic similarities to angiomyofibroblastoma and spindle cell lipoma.
  • Herein we describe a tumor arising in the perineal region of a 60-year-old man with morphological and immunohistochemical features of cellular angiofibroma and showing cytogenetic characteristics similar to spindle cell lipoma.
  • The genetic overlap of these entities supports their origin from the same mesenchymal stem cell.
  • [MeSH-major] Angiofibroma / pathology. Lipoma / pathology. Mesenchymal Stromal Cells / pathology. Nevus, Spindle Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17854668.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Ghazali N, Cascarini L, Norris P, Barrett AW, Lavery KM: Perivascular epithelioid cell tumor (PEComa) of the cheek. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jul;110(1):e26-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perivascular epithelioid cell tumor (PEComa) of the cheek.
  • We present the unusual case of a perivascular epithelioid cell tumor (PEComa) occurring within the cheek of a 32-year-old woman.
  • It mainly affects the abdominopelvic region and rarely occurs in somatic soft tissue or skin.
  • Other possible diagnoses considered included benign mesenchymal tumors of smooth muscle or neural origin.
  • The tumor was completely excised, but in view of uncertainty as to how this entity would behave in an unusual location, lifelong follow up is recommended.
  • [MeSH-major] Cheek / pathology. Facial Neoplasms / diagnosis. Perivascular Epithelioid Cell Neoplasms / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Actins / analysis. Adult. Antigens, Neoplasm / analysis. Arterioles / pathology. Diagnosis, Differential. Epithelioid Cells / pathology. Female. Follow-Up Studies. Humans. MART-1 Antigen. Muscle, Smooth, Vascular / pathology. Neoplasm Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20610292.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, Neoplasm; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins
  •  go-up   go-down


29. Pontes HA, Pontes FS, Silva BS, Cury SE, Fonseca FP, Salim RA, Pinto Júnior Ddos S: Immunoexpression of Ki67, proliferative cell nuclear antigen, and Bcl-2 proteins in a case of ameloblastic fibrosarcoma. Ann Diagn Pathol; 2010 Dec;14(6):447-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoexpression of Ki67, proliferative cell nuclear antigen, and Bcl-2 proteins in a case of ameloblastic fibrosarcoma.
  • Ameloblastic fibrosarcoma (AFS), regarded as the malignant counterpart of the benign ameloblastic fibroma, is an extremely rare odontogenic neoplasm with only 68 cases reported in the English literature up to 2009.
  • It is composed of a benign odontogenic epithelium, resembling that of ameloblastoma, and a malignant mesenchymal part exhibiting features of fibrosarcoma.
  • Due to the rarity of the lesion, little is known about its molecular pathogenesis; therefore, in the current study, we sought to evaluate the immunoexpression of Ki67, proliferative cell nuclear antigen, and Bcl-2 proteins in AFS, comparing the results obtained with its benign counterpart, as well as to report a new case of this rare entity affecting a 19-year-old female patient.
  • The results obtained revealed that all the proteins evaluated were overexpressed in the malignant mesenchymal portion of AFS if compared with ameloblastic fibroma, suggesting that nuclear proliferative factors such as Ki67 and proliferative cell nuclear antigen, in association to histopathologic features, may be useful markers for identifying the malignancy and that, despite the lack of molecular analysis in the case reported, Bcl-2 alteration may play a role in AFS pathogenesis.
  • [MeSH-major] Fibrosarcoma / metabolism. Ki-67 Antigen / metabolism. Mandibular Neoplasms / metabolism. Odontogenic Tumors / metabolism. Proliferating Cell Nuclear Antigen / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Adult. Ameloblasts / metabolism. Ameloblasts / pathology. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Female. Humans

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21074695.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


30. Behzatoğlu K, Durak H, Canberk S, Aydin O, Huq GE, Oznur M, Ozyalvaçli G, Yildiz P: Giant cell tumor-like lesion of the urinary bladder: a report of two cases and literature review; giant cell tumor or undifferentiated carcinoma? Diagn Pathol; 2009;4:48

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor-like lesion of the urinary bladder: a report of two cases and literature review; giant cell tumor or undifferentiated carcinoma?
  • Giant cell tumor, excluding its prototype in bone, is usually a benign but local aggressive neoplasm originating from tendon sheath or soft tissue.
  • Giant cell tumors in visceral organs usually accompany epithelial tumors and the clinical behavior of giant cell tumor in urinary bladder is similar to its bone counterpart.
  • Here, we report two cases of giant cell tumor located in urinary bladder in comparison with nine reported cases in the English literature.
  • One of the two cases we present had no concurrent urothelial tumor at the time of diagnosis but had a history of a low grade noninvasive urothelial carcinoma with three recurrences.
  • The histology of these two cases was similar to the giant cell tumor of bone and composed of oval to spindle mononuclear cells with evenly spaced osteoclast-like giant cells.
  • Immunohistochemical expression of vimentin, CD68, LCA, and smooth muscle actin in mononuclear cells supported a mesenchymal origin with histiocytic lineage.
  • The histologic and immunohistochemical properties in our cases as well as their clinical courses were consistent with a giant cell tumor.
  • Consequently, tumors in urinary bladder showing features of giant cell tumor of bone may also be considered and termed "giant cell tumor".

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1998 Apr 1;82(7):1279-87 [9529019.001]
  • [Cites] J Urol. 2002 Apr;167(4):1784 [11912413.001]
  • [Cites] J Orthop Sci. 2005 Nov;10(6):581-8 [16307183.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):161-71 [16322750.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):495-500 [16625096.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2007 Feb;264(2):205-8 [16977452.001]
  • [Cites] Mod Pathol. 2001 Dec;14(12):1209-15 [11743042.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1467-76 [12409723.001]
  • [Cites] Pathol Int. 2003 Jul;53(7):450-6 [12828610.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):440-3 [15043462.001]
  • [Cites] BMC Urol. 2004 Jun 18;4:7 [15207006.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):953-61 [15223968.001]
  • [Cites] Cancer. 1973 Mar;31(3):621-5 [4693590.001]
  • [Cites] Am J Clin Pathol. 1984 May;81(5):666-75 [6326564.001]
  • [Cites] J Urol. 1985 Mar;133(3):472-5 [3974000.001]
  • [Cites] J Urol. 1989 Jul;142(1):120-2 [2733086.001]
  • [Cites] Arch Pathol Lab Med. 1987 Jan;111(1):43-8 [2432851.001]
  • [Cites] Am J Surg Pathol. 1991 Feb;15(2):160-8 [1989464.001]
  • [Cites] Histopathology. 1990 Nov;17(5):413-8 [1706298.001]
  • [Cites] J Oral Pathol Med. 1999 Feb;28(2):54-8 [9950250.001]
  • (PMID = 20043822.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2811699
  •  go-up   go-down


31. Rego A, Amado J, Esteves I, Almeida J, Furtado A, Couceiro A, Moura e Sá J: [Endobronchial granular cell tumor - what approach to take]. Rev Port Pneumol; 2006 Jul-Aug;12(4):463-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endobronchial granular cell tumor - what approach to take].
  • [Transliterated title] Tumor de células granulares endobrônquico - Como abordamos?
  • Granular cell tumor is a mesenchymal neoplasm almost always benign, with tendency to recurrence.
  • The authors describe two cases of endobronchial granular cell tumours, discuss the particularities of this pathology as well as the treatment options, with particular attention to the use of endobronchial excision and criotherapy.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Bronchial Neoplasms / therapy. Granular Cell Tumor / diagnosis. Granular Cell Tumor / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969575.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


32. Gomez-Moyano E, Vera-Casaño A, Martinez-Garcia S, Sanz-Trelles A, Crespo-Erchiga V: Two cases of dermatomyofibroma (plaque-like dermal fibromatosis). Int J Dermatol; 2010 Aug;49(8):914-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Dermatomyofibroma is a rare but distinct benign cutaneous mesenchymal neoplasm of fibroblastic/myofibroblastic differentiation.
  • In both cases, histological examination showed a spindle-cell proliferation embedded among the collagen fibers of the dermis, arranged predominantly parallel to the skin surface.
  • CONCLUSION: Dermatologists and pediatricians should be aware of this benign entity in order to avoid unnecessary treatment.
  • [MeSH-major] Dermis / pathology. Fibroblasts / pathology. Histiocytoma, Benign Fibrous / diagnosis. Muscle, Smooth / pathology. Skin Neoplasms / diagnosis
  • [MeSH-minor] Cell Division. Female. Humans. Infant. Male. Middle Aged

  • Genetic Alliance. consumer health - Fibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The International Society of Dermatology.
  • (PMID = 21174375.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Yang YP, Zhu YL, Wu WP, Wang ZM, Zhang JM: [Perivascular epithelioid cell tumor of uterus: report of 5 cases and literature review]. Zhonghua Bing Li Xue Za Zhi; 2007 May;36(5):302-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Perivascular epithelioid cell tumor of uterus: report of 5 cases and literature review].
  • OBJECTIVE: To study the pathologic features, diagnosis, differential diagnosis and biologic behavior of uterine perivascular epithelioid tumor.
  • METHODS: Five cases of uterine perivascular epithelioid cell tumor were studied by light microscopy and immunohistochemistry.
  • Immunohistochemically, the tumor cells demonstrated positive staining for melanocytic markers (HMB45 and/or Melan-A), desmin and smooth muscle actin.
  • CONCLUSIONS: Perivascular epithelioid cell tumor is a rare mesenchymal tumor of uterus, with distinctive histologic and immunohistochemical features.
  • It should be distinguished from clear cell carcinoma and epithelioid leiomyoma of uterus.
  • Positivity for melanocytic markers (especially HMB45) plays an important role in the diagnosis of this tumor.
  • In general, the tumor is categorized as benign, with uncertain malignant potential and malignant.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Neoplasm Proteins / metabolism. Perivascular Epithelioid Cell Neoplasms / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adult. Desmin / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Immunohistochemistry. Leiomyoma, Epithelioid / pathology. Melanoma-Specific Antigens. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706136.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Desmin; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  • [Number-of-references] 24
  •  go-up   go-down


34. Kandemir NO, Barut F, Ekinci T, Karagülle C, Ozdamar SO: Intranodal palisaded myofibroblastoma (intranodal hemorrhagic spindle cell tumor with amianthoid fibers): a case report and literature review. Diagn Pathol; 2010;5:12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intranodal palisaded myofibroblastoma (intranodal hemorrhagic spindle cell tumor with amianthoid fibers): a case report and literature review.
  • Intranodal palisaded myofibroblastoma (IPM) is a benign mesenchymal neoplasm originating from smooth muscle cells and myofibroblasts.
  • Microscopic examination revealed spindle cell proliferation, amianthoid fibers, hemosiderin pigment, and extravasated erythrocytes.
  • Compressed lymphoid tissue was observed around the lesion.
  • IPM is an uncommon neoplasm originating from the stromal component of the lymph node.
  • Although IPM is benign, it is frequently confused with metastatic lesions.
  • [MeSH-major] Lymph Nodes / pathology. Neoplasms, Muscle Tissue / pathology
  • [MeSH-minor] Actins / analysis. Aged, 80 and over. Biomarkers, Tumor / analysis. Cell Proliferation. Groin. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Lymph Node Excision. Male. Staining and Labeling. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Cytol. 2002 Nov-Dec;46(6):1143-7 [12462097.001]
  • [Cites] Arch Pathol Lab Med. 2003 Aug;127(8):1040-3 [12873184.001]
  • [Cites] Int Surg. 1968 Mar;49(3):226-30 [5672888.001]
  • [Cites] Isr J Med Sci. 1974 Sep;10(9):1156-5 [4436041.001]
  • [Cites] Am J Surg Pathol. 1989 May;13(5):341-6 [2712186.001]
  • [Cites] Am J Surg Pathol. 1989 May;13(5):347-57 [2712187.001]
  • [Cites] Arch Pathol Lab Med. 2007 Feb;131(2):306-10 [17284119.001]
  • [Cites] Histopathology. 1990 Mar;16(3):287-93 [2332214.001]
  • [Cites] Am J Clin Pathol. 1992 Jan;97(1):69-72 [1728866.001]
  • [Cites] Pathol Res Pract. 1992 Feb;188(1-2):199-204 [1594491.001]
  • [Cites] Chin Med J (Engl). 2005 Oct 20;118(20):1758-60 [16313766.001]
  • [Cites] Anticancer Res. 2006 May-Jun;26(3B):2349-52 [16821615.001]
  • [Cites] Arch Pathol Lab Med. 1989 May;113(5):547-50 [2712680.001]
  • (PMID = 20181136.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Vimentin
  • [Other-IDs] NLM/ PMC2829510
  • [General-notes] NLM/ Original DateCompleted: 20100524
  •  go-up   go-down


35. Andrade ES, Filho JR, Rocha NS, Neto IC, Camargo IB: Isolated intra-oral granular cell tumor: report of two cases and review of the literature. Acta Odontol Latinoam; 2010;23(2):99-104

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated intra-oral granular cell tumor: report of two cases and review of the literature.
  • Granular cell tumor (GCT) is a relatively uncommon lesion occurring in almost any part of the body, including the orofacial region.
  • Although aggressive and malignant variants of this neoplasm have been described, most GCTs are benign.
  • However, histochemical and ultra-structural studies propose the origin of the lesion from Schwann cells, striated muscle, mesenchymal cells, histiocytes and epithelial cells.
  • The tumor generally occurs in middle-aged or older adults.
  • As most granular cell tumors are benign, surgical excision of the lesion is the treatment of choice.
  • Differential diagnoses include fibrous hyperplasia, minor salivary gland tumor condyloma acuminatum and neurilemmoma.
  • The main clinical pathology and diagnostic features of this neoplasm are reviewed and discussed.
  • [MeSH-major] Granular Cell Tumor / pathology. Tongue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053681.001).
  • [ISSN] 0326-4815
  • [Journal-full-title] Acta odontológica latinoamericana : AOL
  • [ISO-abbreviation] Acta Odontol Latinoam
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Argentina
  •  go-up   go-down


36. Lemos MM, Karlen J, Tani E: Fine-needle aspiration cytology of angiomatoid malignant fibrous histiocytoma. Diagn Cytopathol; 2005 Aug;33(2):116-21
Genetic Alliance. consumer health - Histiocytoma, angiomatoid fibrous.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiomatoid malignant fibrous histiocytoma (AMFH) is a rare, low-grade malignant mesenchymal neoplasm that affects mostly the extremities of children and young adults.
  • Cytologic smears showed histiocyte-like cells dispersed and in clusters, in close relation with eosinophilic mesenchymal fragments in a bloody background with lymphocytes.
  • The tumor cells showed mild to moderate anisocariosis, often with nucleolus and vast, fragile cytoplasm.
  • A fibroblastic-like spindle to ovoid cell population was also present in one patient.
  • Immunohistochemical results are most consistent with myofibroblastic cell differentiation.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Muscle Neoplasms / pathology
  • [MeSH-minor] Adolescent. Biopsy, Fine-Needle. Cell Differentiation. Cell Nucleus / metabolism. Cell Nucleus / pathology. Child, Preschool. Female. Fibroblasts / metabolism. Fibroblasts / pathology. Humans. Myoblasts, Skeletal / metabolism. Myoblasts, Skeletal / pathology

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16007669.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Agostini T, Catelani C, Acocella A, Franchi A, Bertolai R, Sacco R, Lazzeri D, Shokrollahi K: Spindle cell liposarcoma of the face: case report and literature review. Br J Dermatol; 2010 Sep;163(3):638-40
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for spindle cell liposarcoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spindle cell liposarcoma of the face: case report and literature review.
  • Liposarcoma is a common soft tissue sarcoma accounting for approximately 20% of all mesenchymal tumours across all ages.
  • Recently, collaborative research in the specialties of pathology and genetics has led to the delineation of several tumour variants with different behaviours and prognoses, one of which includes the very rare spindle cell liposarcoma (SCL) subtype.
  • We present the first case of an SCL arising in the subcutaneous tissue of the forehead of a 78-year-old man.
  • In light of the rarity of this tumour, we describe the tumour and its clinical and pathological characteristics and undertake a literature review to clarify the surgical management and prognosis of SCL, and increase awareness to avoid misdiagnosis of a benign soft tissue neoplasm.

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal Compilation © 2010 British Association of Dermatologists.
  • (PMID = 20456346.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


38. Sibony M, Vieillefond A: [Non clear cell renal cell carcinoma. 2008 update in renal tumor pathology]. Ann Pathol; 2008 Oct;28(5):381-401
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non clear cell renal cell carcinoma. 2008 update in renal tumor pathology].
  • Non clear cell renal cell carcinomas represent almost 20% of all renal neoplasms.
  • Papillary renal cell carcinomas are the most important group and its classification is more and more complex.
  • It encompasses low-grade papillary carcinomas (type 1 papillary renal cell carcinoma, oncocytic papillary renal cell carcinoma) and high-grade papillary carcinomas (type 2 papillary renal cell carcinoma, juvenile papillary carcinoma corresponding to renal carcinoma associated with Xp11.2 translocations and unclassified carcinomas).
  • Mucinous tubular and spindle cell carcinoma and tubulocystic carcinoma are new entities, actually considered by some authors as low-grade papillary carcinomas.
  • Sarcomatoid carcinoma derives from morphological progression of any type of renal cell carcinoma.
  • The group of oncocytomas/chromophobe renal cell carcinomas can be considered as a spectrum from benign (oncocytoma) to malignant neoplasm (chromophobe renal cell carcinoma).
  • Angiomyolipoma is usually a benign mesenchymatous neoplasm, that can be sporadic or familial (tuberous sclerosis).
  • Renal epithelial and stromal tumors (REST) is a new concept gathering two benign mixed mesenchymal and epithelial tumors: cystic nephroma and mixed epithelial and stromal tumors (MEST).
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068393.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 84
  •  go-up   go-down


39. Basu D, Sengupta A, Adhikari D, Dam A, Anwar T: Granular cell myoblastoma of the tongue in a 2-year-old girl: a case report. J Indian Med Assoc; 2010 Mar;108(3):170, 175
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell myoblastoma of the tongue in a 2-year-old girl: a case report.
  • Granular cell tumours are uncommon lesions, although the head and neck region accounts for approximately 50% of all lesions.
  • It is not clear whether or not granular cell tumour is a true neoplasm, a developmental anomaly, or a trauma-induced proliferation.
  • The basic cell of origin is now thought to be neural, although past reports frequently indicated an origin from striated muscle, or less frequently an origin from histiocytes, fibroblasts or pericytes.
  • More than a third of all granular cell tumours occur on the lingual dorsum, usually as a sessile, painless, somewhat firm, immoveable nodule less than 1.5 cm in greatest diameter.
  • Histochemical and ultrastructural studies propose the origin of the lesion from Schwann cells, striated muscle, mesenchymal cells, histiocytes and epithelial cells.
  • As most of the granular cell tumours are benign, surgical excision of the lesion is the treatment of choice.
  • [MeSH-major] Granular Cell Tumor / pathology. Tongue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21043356.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


40. Pickhardt PJ, Bhalla S: Primary neoplasms of peritoneal and sub-peritoneal origin: CT findings. Radiographics; 2005 Jul-Aug;25(4):983-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary neoplasms of peritoneal and sub-peritoneal origin occur much less frequently than metastatic peritoneal involvement from a known or occult primary tumor; however, these rare primary lesions (peritoneal mesothelioma, papillary serous carcinoma, desmoplastic small round cell tumor, benign and malignant mesenchymal tumors, lymphoproliferative disorders) are often first detected at computed tomography (CT) and should be considered in the absence of a known or suspected organ-based malignancy.
  • Furthermore, distinguishing a benign from a malignant process and a primary from a metastatic process is also challenging.
  • Nevertheless, CT features combined with the patient's relevant clinical and demographic data can help narrow the differential diagnosis for a peritoneum-based neoplasm in many cases.
  • CT is useful not only for the detection, characterization, and staging of primary neoplasms of peritoneal and subperitoneal origin, but also for guiding biopsy for tissue diagnosis.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16009819.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


41. Sepe PS, Brugge WR: A guide for the diagnosis and management of gastrointestinal stromal cell tumors. Nat Rev Gastroenterol Hepatol; 2009 Jun;6(6):363-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A guide for the diagnosis and management of gastrointestinal stromal cell tumors.
  • Gastrointestinal stromal cell tumors (GISTs) are the most common mesenchymal neoplasm of the gastrointestinal tract and are frequently detected on routine endoscopy.
  • Preoperative determination of malignancy risk can be estimated from tumor size and location, but reliable histopathologic criteria are not currently available.
  • Given such biological uncertainty, accurate diagnosis is essential to differentiate these lesions from other truly benign, subepithelial tumors.
  • Endoscopic ultrasound-guided fine-needle aspiration has emerged as an important procedure to secure a tissue diagnosis of a GIST.

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19365407.001).
  • [ISSN] 1759-5053
  • [Journal-full-title] Nature reviews. Gastroenterology & hepatology
  • [ISO-abbreviation] Nat Rev Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 91
  •  go-up   go-down


42. Carinci F, Piattelli A, Martinelli M, Palmieri A, Rubini C, Fioroni M, Scapoli L, Laino G, Caputi S, Becchetti A, Pezzetti F: Genetic profiling of central giant cell granuloma of the jaws. J Craniofac Surg; 2005 May;16(3):399-407
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic profiling of central giant cell granuloma of the jaws.
  • Central giant cell granuloma (CGCG) of the jaws is a central osteolytic lesion characterized histologically by multinucleated giant cells in a background of ovoid to spindle-shaped mesenchymal cells.
  • Whether CGCG is a reactive lesion or a truly benign neoplasm remains undetermined, and the mechanism determining the onset of the disease remains unknown.
  • RNA extracted from a pool of three normal bone tissues was used as control.
  • The differentially expressed genes cover a broad range of functional activities: cell cycle regulation; signal transduction; and vesicular transport.
  • [MeSH-major] Gene Expression Profiling. Granuloma, Giant Cell / genetics. Mandibular Diseases / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15915104.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


43. Thompson LD, Karamurzin Y, Wu ML, Kim JH: Solitary fibrous tumor of the larynx. Head Neck Pathol; 2008 Jun;2(2):67-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the larynx.
  • BACKGROUND: True mesenchymal, non-cartilaginous neoplasms of the larynx are rare.
  • Extrapleural solitary fibrous tumor (SFT) is a localized neoplasm characterized by proliferation of thin-walled vessels and collagen-producing cells and is considered within the "hemangiopericytoma-solitary fibrous tumor" spectrum.
  • A cellular, spindle cell neoplasm was arranged in loose fascicles, associated with heavy collagen fiber deposition.
  • These findings confirmed a diagnosis of extraplural solitary fibrous tumor.
  • CONCLUSIONS: The characteristic histologic pattern of solitary fibrous tumor can be noted in extrapulmonary locations.
  • Development in the larynx is uncommon, but the tumor presents as a polypoid mass with characteristic histologic and immunophenotypic features.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Disease-Free Survival. Humans. Male. Middle Aged. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Otolaryngol Head Neck Surg. 2005 Jul;133(1):163-5 [16025074.001]
  • [Cites] Arch Pathol Lab Med. 2006 Feb;130(2):213-6 [16454566.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 May;134(5):880-2 [16647552.001]
  • [Cites] Auris Nasus Larynx. 2007 Sep;34(3):405-8 [17337142.001]
  • [Cites] Mod Pathol. 1999 Nov;12(11):1034-42 [10574600.001]
  • [Cites] Hum Pathol. 1999 Dec;30(12):1464-73 [10667425.001]
  • [Cites] Virchows Arch. 2000 Sep;437(3):248-55 [11037344.001]
  • [Cites] Laryngoscope. 2001 Jul;111(7):1197-202 [11568541.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):153-70 [11812937.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):1057-68 [11920476.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):737-49 [12766577.001]
  • [Cites] Laryngoscope. 2003 May;113(5):783-90 [12792311.001]
  • [Cites] Cancer. 1979 Feb;43(2):627-35 [421185.001]
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):640-58 [2665534.001]
  • [Cites] J Laryngol Otol. 1993 Mar;107(3):252-6 [8509708.001]
  • [Cites] Am J Surg Pathol. 1994 Oct;18(10):992-8 [7522416.001]
  • [Cites] Am J Surg Pathol. 1995 Nov;19(11):1257-66 [7573687.001]
  • [Cites] J Pathol. 1997 Apr;181(4):362-7 [9196431.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Jun;111(2):169-71 [10347558.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 Apr;262(4):286-8 [15170575.001]
  • [Cites] Mod Pathol. 1997 Oct;10(10):1028-37 [9346183.001]
  • [Cites] Mod Pathol. 1997 Dec;10(12):1194-200 [9436963.001]
  • [Cites] Histopathology. 1997 Dec;31(6):568-76 [9447390.001]
  • [Cites] J Laryngol Otol. 1998 Mar;112(3):286-9 [9624382.001]
  • (PMID = 20614325.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2807554
  • [Keywords] NOTNLM ; Benign neoplasm / CD34 / Fibroma / Hemangiopericytoma / Immunohistochemistry / Larynx / Mesenchymal tumor / Prognosis / Solitary fibrous tumor / Spindle cell squamous cell carcinoma / Surgery / True vocal cord / bcl-2
  •  go-up   go-down


44. Bishop JA, Rekhtman N, Chun J, Wakely PE Jr, Ali SZ: Malignant solitary fibrous tumor: cytopathologic findings and differential diagnosis. Cancer Cytopathol; 2010 Apr 25;118(2):83-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant solitary fibrous tumor: cytopathologic findings and differential diagnosis.
  • BACKGROUND: Malignant solitary fibrous tumors (SFTs) are extremely uncommon and poorly understood mesenchymal neoplasms.
  • FNA smears and cell block material including immunoperoxidase stains were reviewed, and the cytologic characteristics were described.
  • Cytomorphologic features included mostly hypercellular smears with tissue fragments of monotonous, plump spindled cells with blunt-ended and indented nuclei and fragile, wispy cytoplasm.
  • Predominant FNA diagnoses were SFT or spindle cell neoplasm.
  • Malignant SFT must be included in the differential diagnosis of a spindle cell neoplasm of any anatomic site, particularly if it displays features not typical of benign SFT.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasms, Connective Tissue / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society.
  • (PMID = 20209623.001).
  • [ISSN] 1934-662X
  • [Journal-full-title] Cancer cytopathology
  • [ISO-abbreviation] Cancer Cytopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Kobayashi K, Murakami R, Fujii T, Hirano A: Malignant transformation of ameloblastic fibroma to ameloblastic fibrosarcoma: case report and review of the literature. J Craniomaxillofac Surg; 2005 Oct;33(5):352-5
Genetic Alliance. consumer health - Fibrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The epithelial component remains benign, but the mesenchymal component becomes malignant.
  • Knowledge of the malignant potential in the mesenchymal spindle cells of ameloblastic fibroma will assist in determining the management of these benign tumours, and may prevent malignant transformation to ameloblastic fibrosarcoma.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Mandibular Neoplasms / pathology. Odontogenic Tumors / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Follow-Up Studies. Fractures, Spontaneous / pathology. Humans. Male. Mandibular Fractures / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16129612.001).
  • [ISSN] 1010-5182
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Scotland
  • [Number-of-references] 16
  •  go-up   go-down


46. Bertagnolli AC, Soares P, van Asch B, Amorim A, Cirnes L, Máximo V, Cassali GD: An assessment of the clonality of the components of canine mixed mammary tumours by mitochondrial DNA analysis. Vet J; 2009 Nov;182(2):269-74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to investigate if mutations in the mitochondrial DNA (mtDNA) D-loop fragment control region of canine mammary mixed tumours could be used as clonal markers that identified the cell population of origin.
  • Ten benign mixed mammary tumours and nine carcinomas arising from benign mixed tumours were microdissected and DNA from epithelial and mesenchymal tumour cells and from normal mammary tissue was examined for sequence variations in a fragment of the hypervariable control region.
  • Identical sequence variants in both the epithelial and mesenchymal components (as well as in the corresponding normal tissue) were found in 80% of the benign mixed tumours and in 89% of the carcinomas arising from benign mixed tumours suggesting a shared clonal origin.
  • The distinctive sequence alterations identified in the epithelial and mesenchymal components of 15.8% of all 19 tumours examined, suggests the possibility that a minority of mammary tumours are polyclonal in origin or that early clonal divergence occurs.
  • [MeSH-minor] Animals. Clone Cells / pathology. DNA, Neoplasm / chemistry. DNA, Neoplasm / genetics. Dogs. Female. Genetic Variation. Immunohistochemistry / veterinary. Polymerase Chain Reaction / veterinary. Polymorphism, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18752974.001).
  • [ISSN] 1532-2971
  • [Journal-full-title] Veterinary journal (London, England : 1997)
  • [ISO-abbreviation] Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; 0 / DNA, Neoplasm
  •  go-up   go-down


47. Paci M, Cavazza A, Annessi V, Ricchetti T, Rapicetta C, Sgarbi G: Cystic fibrohistiocytic tumor of the lung presenting as a solitary lesion. Rare Tumors; 2010;2(1):e14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic fibrohistiocytic tumor of the lung presenting as a solitary lesion.
  • Cystic fibrohistiocytic tumor of the lung is a rare neoplasm.
  • In many cases it represents a metastasis from a benign or low-grade fibrohistiocytic tumor of the skin, but occasionally it may be primary.
  • Microscopy of the apical segmentectomy showed a cystic fibrohistiocytic tumor, whereas the nodule of the lower lobe was an intraparenchymal lymph node.
  • The patient is alive with no tumor recurrence.
  • The differential diagnosis includes Langerhans cell histiocytosis, lymphangioleiomyomatosis, pleuropulmonary blastoma, and metastatic endometrial stromal sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139943.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994490
  • [Keywords] NOTNLM ; cystic fibrohistiocytic tumor / lung neoplasms / mesenchymal cystic hamartoma / mesenchymal tumors / metastases / pneumothorax
  •  go-up   go-down


48. Garrido Abad P, Coloma del Peso A, Jiménez Gálvez M, Herranz Fernández LM, Arellano Gañán R, Reina Durán T: [Inflammatory myofibroblastic tumor. Case report]. Arch Esp Urol; 2008 Jan-Feb;61(1):62-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inflammatory myofibroblastic tumor. Case report].
  • [Transliterated title] Tumor miofibroblástico inflamatorio vesical. Aportación de un nuevo caso.
  • OBJECTIVE: To report one case of myofibroblastic bladder tumor.
  • After TUR, inflammatory myofibroblastic tumor of the bladder was diagnosed.
  • CONCLUSION: Myofibroblastic tumor (also known as inflammatory pseudotumor or pseudosarcoma) is a benign tumor with mesenchymal origin.
  • It must not be misdiagnosed as a malignant neoplasm.
  • [MeSH-major] Leydig Cell Tumor / pathology. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18405029.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


49. Rekhi B, Bhatnagar D, Bhatnagar A, Saxena S: Cytomorphological study of soft tissue neoplasms: role of fluorescent immunocytochemistry in diagnosis. Cytopathology; 2005 Oct;16(5):219-26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphological study of soft tissue neoplasms: role of fluorescent immunocytochemistry in diagnosis.
  • OBJECTIVES: Exact categorization of soft tissue tumours (STTs) on smears requires application of various ancillary techniques.
  • METHODS: Thirty cases of soft tissue tumours were included in the present study.
  • RESULTS: Among the 30 cases in the present study, unaided cytological diagnoses ranged from 'spindle cell' tumour in four (13.3%) cases, benign and malignant spindle cell tumour in 17 (56.6%) cases, to malignant mesenchymal tumour in nine (30%) cases.
  • FICC helped in further correct categorization of 25/30 (83.3%) cases viz. leiomyoma (three), benign neurogenic tumour (six), schwannoma (one), dermatofibrosarcoma protuberans (three), synovial sarcoma (two), rhabdomyosarcoma (two), malignant fibrous histiocytoma (five) and malignant peripheral nerve sheath tumour (three).
  • [MeSH-major] Neoplasm Proteins. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16181307.001).
  • [ISSN] 0956-5507
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


50. Zustin J, Akpalo H, Gambarotti M, Priemel M, Rueger JM, Luebke AM, Reske D, Lange C, Pueschel K, Lohmann C, Rüther W, Amling M, Alberghini M: Phenotypic diversity in chondromyxoid fibroma reveals differentiation pattern of tumor mimicking fetal cartilage canals development: an immunohistochemical study. Am J Pathol; 2010 Sep;177(3):1072-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic diversity in chondromyxoid fibroma reveals differentiation pattern of tumor mimicking fetal cartilage canals development: an immunohistochemical study.
  • Chondromyxoid fibroma represents a rare benign cartilaginous tumor of young patients occurring in a subcortical metaphyseal location.
  • The histogenesis of chondromyxoid fibroma has not yet been postulated, even though the conventional histology and recent immunohistochemical studies on phenotype of the mesenchymal cells and extracellular matrix components suggested its origin in immature cartilage.
  • Therefore, we wished to compare the morphological pattern of immature cartilage tissue with chondromyxoid fibroma to investigate a possible developmental counterpart of chondromyxoid fibroma.
  • Vascularized cartilage canals growing into the fetal cartilage from the perichondrium displayed characteristic glomeruloid structures with central arterioles within the immature mesenchymal stroma and numerous superficial sinusoidal blood vessels accompanied by macrophage infiltration.
  • Similarly, each case of chondromyxoid fibroma demonstrated admixture of two characteristic components: immature fibrous tissue of vascularized stroma with accumulation of macrophages in areas of superficial sinusoidal proliferation, and variable amounts of lobulated chondroid tissue.
  • Based on the observed substantial morphological similarity between the cartilage canals and chondromyxoid fibroma, we suggest that the chondromyxoid fibroma represents a neoplasm originating from or mimicking the fetal cartilage canals within the immature cartilage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2001 Aug;116(2):271-7 [11488075.001]
  • [Cites] J Bone Miner Res. 2010 Jun;25(6):1267-81 [20200945.001]
  • [Cites] J Pediatr Orthop. 2002 Mar-Apr;22(2):217-8 [11856934.001]
  • [Cites] Bone. 2004 Mar;34(3):454-65 [15003793.001]
  • [Cites] J Bone Joint Surg Br. 1971 May;53(2):198-216 [5578216.001]
  • [Cites] Anat Rec. 1972 May;173(1):79-93 [5028066.001]
  • [Cites] Hum Pathol. 1979 Jan;10(1):71-86 [428995.001]
  • [Cites] Acta Pathol Jpn. 1984 Nov;34(6):1285-300 [6524378.001]
  • [Cites] Acta Anat (Basel). 1985;124(1-2):54-7 [4072610.001]
  • [Cites] AJR Am J Roentgenol. 1986 Aug;147(2):317-21 [3524161.001]
  • [Cites] Tissue Cell. 1986;18(5):701-7 [3775757.001]
  • [Cites] Mod Pathol. 1990 Nov;3(6):664-6 [2263591.001]
  • [Cites] J Cell Biochem. 1996 Jul;62(1):1-9 [8836870.001]
  • [Cites] Hum Pathol. 1998 May;29(5):438-46 [9596266.001]
  • [Cites] Anat Rec. 1998 Sep;252(1):140-8 [9737750.001]
  • [Cites] Mod Pathol. 1999 May;12(5):514-7 [10349990.001]
  • [Cites] J Anat. 2005 Apr;206(4):359-72 [15817104.001]
  • [Cites] J Pathol. 2005 Jun;206(2):135-42 [15880456.001]
  • [Cites] J Pathol. 2006 Jan;208(1):26-34 [16278817.001]
  • [Cites] Am J Pathol. 2007 Jun;170(6):1807-16 [17525249.001]
  • [Cites] Dev Dyn. 2007 Aug;236(8):2077-88 [17626280.001]
  • [Cites] Ann Anat. 2008;190(4):305-15 [18602255.001]
  • [Cites] APMIS. 2009 Jul;117(7):518-25 [19594492.001]
  • [Cites] Adv Anat Pathol. 2009 Sep;16(5):307-15 [19700940.001]
  • [Cites] Dev Biol. 2010 May 1;341(1):236-45 [20206617.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):1009-20 [11549593.001]
  • (PMID = 20671262.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2928941
  •  go-up   go-down


51. Waldmann J, Feldmann G, Slater EP, Langer P, Buchholz M, Ramaswamy A, Saeger W, Rothmund M, Fendrich V: Expression of the zinc-finger transcription factor Snail in adrenocortical carcinoma is associated with decreased survival. Br J Cancer; 2008 Dec 2;99(11):1900-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One of the best known functions of the zinc-finger transcription factor Snail is to induce epithelial-to-mesenchymal transition (EMT).
  • Snail expression was neither detected in normal adrenocortical tissue, nor in benign adrenocortical adenomas.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / metabolism. Biomarkers, Tumor / analysis. Transcription Factors / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Cadherins / biosynthesis. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Ki-67 Antigen / biosynthesis. Male. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1998 Mar 12;392(6672):190-3 [9515965.001]
  • [Cites] Horm Res. 1997;47(4-6):279-83 [9167965.001]
  • [Cites] Physiol Rev. 1959 Jan;39(1):162-82 [13623432.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):252-8 [15668718.001]
  • [Cites] Dig Dis Sci. 2005 Jan;50(1):42-6 [15712635.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1631-43 [15742334.001]
  • [Cites] Cell Cycle. 2005 Jun;4(6):772-6 [15917668.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7622-7 [16140927.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):548-58 [16098727.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):197-209 [16169465.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 [16493418.001]
  • [Cites] Eur J Endocrinol. 2006 Apr;154(4):587-98 [16556722.001]
  • [Cites] Oncol Rep. 2006 Jul;16(1):65-71 [16786124.001]
  • [Cites] Jpn J Clin Oncol. 2006 Jun;36(6):357-63 [16766568.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5395-402 [17000672.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jan;92(1):148-54 [17062775.001]
  • [Cites] Breast Cancer Res. 2006;8(4):105 [16834762.001]
  • [Cites] Endocr Pathol. 2006 Winter;17(4):345-54 [17525483.001]
  • [Cites] Histopathology. 2007 Aug;51(2):239-45 [17593212.001]
  • [Cites] Endocr Relat Cancer. 2007 Sep;14(3):865-74 [17914115.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):711-36 [10679640.001]
  • [Cites] Mol Cell. 2001 Jun;7(6):1267-78 [11430829.001]
  • [Cites] Eur J Endocrinol. 2001 Sep;145(3):335-41 [11517015.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1113-21 [11571723.001]
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1613-8 [11912130.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):521-31 [12547710.001]
  • [Cites] Am J Clin Pathol. 2004 Jul;122(1):78-84 [15272533.001]
  • [Cites] Development. 2004 Sep;131(17):4213-24 [15280211.001]
  • [Cites] Nat Cell Biol. 2004 Oct;6(10):931-40 [15448698.001]
  • [Cites] Am J Clin Pathol. 1979 Sep;72(3):390-9 [474519.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):766-73 [3967172.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Endocrinology. 1990 Jun;126(6):3251-62 [2161753.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1303-9 [9137490.001]
  • [Cites] Horm Metab Res. 1998 Jun-Jul;30(6-7):421-5 [9694573.001]
  • (PMID = 19018264.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Ki-67 Antigen; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / snail family transcription factors
  • [Other-IDs] NLM/ PMC2600683
  •  go-up   go-down


52. Shintani Y, Fukumoto Y, Chaika N, Svoboda R, Wheelock MJ, Johnson KR: Collagen I-mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1. J Cell Biol; 2008 Mar 24;180(6):1277-89
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor cells undergo epithelial-to-mesenchymal transition (EMT) to convert from a benign to a malignant phenotype.
  • We have shown that human pancreatic cancer cells respond to collagen by up-regulating N-cadherin, which promotes tumor growth, invasion, and metastasis.
  • Initial characterization showed that knocking down c-Jun NH2-terminal kinase prevented N-cadherin up-regulation and limited tumor growth and invasion in a mouse model for pancreatic cancer.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2002 Feb 15;295(5558):1285-8 [11847339.001]
  • [Cites] Nat Cell Biol. 2002 Apr;4(4):E83-90 [11944041.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2001-8 [12057905.001]
  • [Cites] BMC Cell Biol. 2002 Jul 15;3:18 [12119061.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):32970-7 [12087088.001]
  • [Cites] Cell. 2002 Sep 20;110(6):673-87 [12297042.001]
  • [Cites] J Cell Biol. 2002 Nov 11;159(3):465-76 [12427869.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6688-97 [12438268.001]
  • [Cites] Dev Cell. 2003 Jan;4(1):11-8 [12530959.001]
  • [Cites] Cell. 2003 Mar 7;112(5):673-84 [12628187.001]
  • [Cites] J Biol Chem. 2003 May 9;278(19):17269-76 [12604612.001]
  • [Cites] Cell. 2003 Jun 13;113(6):685-700 [12809600.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Aug;4(8):657-65 [12923528.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):45801-10 [12954618.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):740-6 [14644200.001]
  • [Cites] J Am Soc Nephrol. 2004 Jan;15(1):1-12 [14694152.001]
  • [Cites] Front Biosci. 2004 May 1;9:1254-66 [14977542.001]
  • [Cites] Trends Biochem Sci. 2004 May;29(5):265-73 [15130563.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):14-9 [9426049.001]
  • [Cites] J Biol Chem. 1998 Jan 16;273(3):1281-4 [9430657.001]
  • [Cites] Trends Cell Biol. 1998 Apr;8(4):151-7 [9695829.001]
  • [Cites] J Cell Biol. 1998 Nov 30;143(5):1385-98 [9832565.001]
  • [Cites] Biochim Biophys Acta. 2004 Jul 5;1692(2-3):63-76 [15246680.001]
  • [Cites] J Biol Chem. 2004 Jul 23;279(30):31041-9 [15143071.001]
  • [Cites] J Cell Biol. 2004 Jul 19;166(2):283-95 [15263022.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33315-22 [15166227.001]
  • [Cites] Oncogene. 2004 Aug 5;23(35):5978-85 [15184866.001]
  • [Cites] J Biol Chem. 2004 Aug 20;279(34):35127-32 [15166221.001]
  • [Cites] J Cell Sci. 2004 Sep 15;117(Pt 20):4691-703 [15331629.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26 [15459662.001]
  • [Cites] J Cell Biol. 2004 Oct 11;167(1):111-22 [15479739.001]
  • [Cites] Respir Res. 2006;7:114 [16948840.001]
  • [Cites] Exp Eye Res. 2006 Dec;83(6):1309-16 [16769055.001]
  • [Cites] Microbiol Mol Biol Rev. 2006 Dec;70(4):1061-95 [17158707.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11745-53 [17178870.001]
  • [Cites] J Cell Sci. 2007 Jan 1;120(Pt 1):17-22 [17182900.001]
  • [Cites] J Am Soc Nephrol. 2007 Mar;18(3):846-59 [17267741.001]
  • [Cites] Cell Signal. 2007 May;19(5):923-31 [17197157.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3106-16 [17409417.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):71-7 [17721921.001]
  • [Cites] Am J Respir Cell Mol Biol. 2008 Jan;38(1):95-104 [17673689.001]
  • [Cites] J Cell Biol. 1999 Nov 1;147(3):631-44 [10545506.001]
  • [Cites] J Biol Chem. 2000 Feb 25;275(8):5779-84 [10681566.001]
  • [Cites] J Cell Biol. 2000 Feb 21;148(4):779-90 [10684258.001]
  • [Cites] J Cell Biol. 2000 Mar 20;148(6):1151-8 [10725328.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3650-4 [10910081.001]
  • [Cites] Curr Biol. 2000 Aug 24;10(16):974-8 [10985384.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3508-17 [11309315.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1313-21 [11583959.001]
  • [Cites] Bioessays. 2001 Oct;23(10):912-23 [11598958.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):5192-6 [1594631.001]
  • [Cites] J Cell Biol. 1993 May;121(3):673-8 [8387531.001]
  • [Cites] Exp Cell Res. 1993 Aug;207(2):252-60 [8344378.001]
  • [Cites] Exp Cell Res. 1994 Apr;211(2):175-82 [8143763.001]
  • [Cites] Pancreas. 1995 Nov;11(4):357-64 [8532652.001]
  • [Cites] J Biol Chem. 1996 Mar 22;271(12):6794-800 [8636102.001]
  • [Cites] J Cell Biol. 1996 Dec;135(6 Pt 1):1643-54 [8978829.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):947-52 [10029089.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2805-10 [10077592.001]
  • [Cites] J Biol Chem. 1999 May 21;274(21):14893-901 [10329689.001]
  • [Cites] J Biol Chem. 1999 Oct 8;274(41):28966-71 [10506143.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7427-37 [15534120.001]
  • [Cites] J Cell Sci. 2005 Mar 1;118(Pt 5):873-87 [15713751.001]
  • [Cites] Cell Oncol. 2005;27(1):3-13 [15750203.001]
  • [Cites] Science. 2005 Mar 11;307(5715):1603-9 [15761148.001]
  • [Cites] Science. 2005 Mar 11;307(5715):1621-5 [15761153.001]
  • [Cites] Curr Opin Cell Biol. 2005 Apr;17(2):123-8 [15780587.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4):907-21 [15825074.001]
  • [Cites] Nature. 2005 Jul 7;436(7047):123-7 [16001073.001]
  • [Cites] J Cell Sci. 2005 Aug 15;118(Pt 16):3573-84 [16105881.001]
  • [Cites] Oncogene. 2005 Aug 29;24(37):5764-74 [16123809.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):898-906 [16424023.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 [16493418.001]
  • [Cites] Oncogene. 2006 Mar 2;25(9):1378-90 [16247454.001]
  • [Cites] J Cell Biol. 2006 Mar 27;172(7):973-81 [16567498.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4662-71 [16651417.001]
  • [Cites] Br J Cancer. 2006 May 8;94(9):1311-9 [16622460.001]
  • [Cites] Cell Signal. 2006 Aug;18(8):1108-16 [16626936.001]
  • [Cites] Trends Cell Biol. 2006 May;16(5):257-63 [16581250.001]
  • [Cites] Mol Biol Cell. 2006 Jul;17(7):2963-75 [16624865.001]
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1321-7 [11677955.001]
  • [Cites] Cancer Lett. 2002 Feb 25;176(2):123-8 [11804738.001]
  • (PMID = 18362184.001).
  • [ISSN] 1540-8140
  • [Journal-full-title] The Journal of cell biology
  • [ISO-abbreviation] J. Cell Biol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01-GM51188; United States / NIDCR NIH HHS / DE / R01-DE12308; United States / NIDCR NIH HHS / DE / R01 DE012308; United States / NCI NIH HHS / CA / P30 CA036727; United States / NCI NIH HHS / CA / P30 CA36727; United States / NIGMS NIH HHS / GM / R01 GM051188
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCAR1 protein, human; 0 / Cadherins; 0 / Collagen Type I; 0 / Crk-Associated Substrate Protein; 0 / Integrin alpha2beta1; 0 / Receptors, Mitogen; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / discoidin receptor; EC 2.7.10.2 / Focal Adhesion Kinase 2; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases; EC 3.6.5.2 / rap1 GTP-Binding Proteins
  • [Other-IDs] NLM/ PMC2290851
  •  go-up   go-down


53. Hameed M: Pathology and genetics of adipocytic tumors. Cytogenet Genome Res; 2007;118(2-4):138-47
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adipocytic tumors are common mesenchymal neoplasms with considerable morphologic and genetic heterogeneity.
  • The current WHO classification includes eleven benign subtypes, one intermediate and five categories of malignant fatty neoplasms with incorporation of relevant genetic findings.
  • Of the benign tumors, lipomas have been extensively analyzed by chromosome banding which has shown that their cytogenetic patterns are heterogeneous.
  • Among the malignant tumors, the t(12;16)(q13;p11) resulting in the fusion of DDIT3 and FUS genes is the hallmark of myxoid and round cell liposarcoma and is used as a highly specific and sensitive marker of this entity.
  • The tumor in the intermediate group, atypical lipomatous neoplasm/well-differentiated liposarcoma which poses morphologic challenges due to close histological similarity to benign lipomas shows characteristic supernumerary rings and giant rod chromosomes due to amplification of the 12q14-->q15 region often involving the MDM2 oncogene.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 18000364.001).
  • [ISSN] 1424-859X
  • [Journal-full-title] Cytogenetic and genome research
  • [ISO-abbreviation] Cytogenet. Genome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 76
  •  go-up   go-down


54. Liu X, Ma YQ, Wang J: [Prepubertal-type vulva fibroma: a clinicopathological study of two cases]. Zhonghua Bing Li Xue Za Zhi; 2010 Jan;39(1):40-3
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Grossly, cut surface of the tumor appeared as the gray fibrous tissue without any definited lump detected.
  • Histologically, the ill-circumscribed lesion located predominantly in the deep dermis with an extension into the subcutaneous tissue.
  • They had a low cell density consisting of scattered spindle shaped fibroblast-like cells and a large amount of collagen fiber matrix, nuclear atypia not seen and mitotic figures scanty.
  • The tumor cells extended downward under the epithelium and infiltrated between the fat tissue, nerve fibers as well as the capillaries making a lesion looked somewhat like a harmatoma.
  • CONCLUSIONS: PVF is a benign mesenchymal lesion with a predilection of involving the vulva of prepubertal girls or adults in rare cases.
  • PVF may represent an overgrowth of normal stromal tissue of vulva.
  • [MeSH-minor] Antigens, CD34 / metabolism. Child. Diagnosis, Differential. Female. Humans. Middle Aged. Myxoma / pathology. Neoplasm Recurrence, Local. Vulva / pathology. Vulva / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20388398.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Vimentin
  •  go-up   go-down


55. Wachter DL, Büttner MJ, Grimm K, Hartmann A, Agaimy A: Leiomyoma of the gallbladder: a case report with review of the literature and discussion of the differential diagnosis. J Clin Pathol; 2010 Feb;63(2):177-9
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesenchymal neoplasms of the gallbladder are rare, and most represent sarcomas of various histological types.
  • Histology and immunohistochemistry were consistent with a benign smooth muscle neoplasm that is very similar to conventional uterine leiomyoma.
  • Leiomyoma should be included in the differential diagnosis of spindle cell tumours of the gallbladder and must be distinguished from leiomyosarcoma and the rare gastrointestinal stromal tumour-like neoplasms reported recently at this unusual anatomical site.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154041.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 10
  •  go-up   go-down


56. Shah GV, Muralidharan A, Gokulgandhi M, Soan K, Thomas S: Cadherin switching and activation of beta-catenin signaling underlie proinvasive actions of calcitonin-calcitonin receptor axis in prostate cancer. J Biol Chem; 2009 Jan 9;284(2):1018-30
Hazardous Substances Data Bank. Calcitonin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Calcitonin, a neuroendocrine peptide, and its receptor are localized in the basal epithelium of benign prostate but in the secretory epithelium of malignant prostates.
  • Moreover, calcitonin increases tumorigenicity and invasiveness of multiple prostate cancer cell lines by cyclic AMP-dependent protein kinase-mediated actions.
  • These actions include increased secretion of matrix metalloproteinases and urokinase-type plasminogen activator and an increase in prostate cancer cell invasion.
  • Activation of calcitonin-calcitonin receptor autocrine loop in prostate cancer cell lines led to the loss of cell-cell adhesion, destabilization of tight and adherens junctions, and internalization of key integral membrane proteins.
  • In addition, the activation of calcitonin-calcitonin receptor axis induced epithelial-mesenchymal transition of prostate cancer cells as characterized by cadherin switch and the expression of the mesenchymal marker, vimentin.
  • These results for the first time identify actions of calcitonin-calcitonin receptor axis on prostate cancer cells that lead to the destabilization of cell-cell junctions, epithelial-to-mesenchymal transition, and activation of WNT/beta-catenin signaling.
  • The results also suggest that cyclic AMP-dependent protein kinase plays a key role in calcitonin receptor-induced destabilization of cell-cell junctions and activation of WNT-beta-catenin signaling.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Biol Ther. 2002 Jul-Aug;1(4):337-41 [12432242.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):11960-5 [11035810.001]
  • [Cites] J Cell Sci. 2003 May 15;116(Pt 10):1959-67 [12668723.001]
  • [Cites] Cancer Sci. 2003 Jul;94(7):575-81 [12841864.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2672-2680 [14755243.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:155-63 [15153430.001]
  • [Cites] N Engl J Med. 2004 May 27;350(22):2239-46 [15163773.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4125-33 [15217949.001]
  • [Cites] Mol Cell. 2004 Aug 27;15(4):511-21 [15327768.001]
  • [Cites] Invest Urol. 1979 Jul;17(1):16-23 [447482.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Aug;79(15):4672-6 [6956885.001]
  • [Cites] Ciba Found Symp. 1988;141:48-74 [3075937.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5190-7 [1382837.001]
  • [Cites] Prostate. 1993;22(2):109-18 [7681204.001]
  • [Cites] Urol Res. 1993;21(5):359-62 [7506464.001]
  • [Cites] Endocrinology. 1994 Feb;134(2):596-602 [8299557.001]
  • [Cites] J Postgrad Med. 1993 Oct-Dec;39(4):197-201 [7996496.001]
  • [Cites] Mol Endocrinol. 1995 Aug;9(8):959-68 [7476993.001]
  • [Cites] Int J Cancer. 2001 Jan 1;91(1):46-54 [11149419.001]
  • [Cites] Prostate. 2001 Feb 1;46(2):142-53 [11170142.001]
  • [Cites] Pathol Int. 2001 Jun;51(6):452-9 [11422807.001]
  • [Cites] Mol Cell Endocrinol. 2001 Jul 5;181(1-2):69-79 [11476942.001]
  • [Cites] Cell Growth Differ. 2001 Dec;12(12):631-40 [11751458.001]
  • [Cites] J Cell Sci. 2002 Nov 15;115(Pt 22):4227-36 [12376555.001]
  • [Cites] Cancer Cell. 2002 Oct;2(4):301-14 [12398894.001]
  • [Cites] Histol Histopathol. 2005 Jan;20(1):197-203 [15578438.001]
  • [Cites] J Cell Sci. 2005 Mar 1;118(Pt 5):873-87 [15713751.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(11):4591-601 [15899862.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8519-29 [16166333.001]
  • [Cites] Int J Cancer. 2005 Nov 20;117(4):551-60 [15929083.001]
  • [Cites] Mol Cell Biol. 2005 Oct;25(20):9063-72 [16199882.001]
  • [Cites] Urol Oncol. 2005 Nov-Dec;23(6):402-6 [16301117.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):6566-78 [16314317.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11649-57 [16357176.001]
  • [Cites] Cancer Biol Ther. 2005 Nov;4(11):1226-33 [16222118.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):46-51 [16397214.001]
  • [Cites] Urol Oncol. 2006 Mar-Apr;24(2):131-40 [16520277.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2694-702 [16381004.001]
  • [Cites] Mol Endocrinol. 2006 Aug;20(8):1894-911 [16574742.001]
  • [Cites] Prostate. 2006 Nov 1;66(15):1664-73 [16902972.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4042-5 [17634527.001]
  • [Cites] J Cell Physiol. 2007 Nov;213(2):374-83 [17680632.001]
  • [Cites] J Surg Oncol. 2007 Oct 1;96(5):419-23 [17874463.001]
  • [Cites] Ernst Schering Found Symp Proc. 2006;(5):27-58 [17939294.001]
  • [Cites] Int J Oncol. 2007 Dec;31(6):1425-37 [17982669.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):7003-11 [18056176.001]
  • [Cites] Cancer Cell. 2007 Dec;12(6):559-71 [18068632.001]
  • [Cites] J Cell Biochem. 2008 May 1;104(1):304-17 [17990294.001]
  • [Cites] Curr Opin Hematol. 2008 Jul;15(4):319-25 [18536569.001]
  • [Cites] Nat Cell Biol. 2003 Feb;5(2):137-42 [12545177.001]
  • [Cites] Am J Physiol. 1995 Oct;269(4 Pt 1):G467-75 [7485497.001]
  • [Cites] Urology. 1996 Mar;47(3):376-81 [8633405.001]
  • [Cites] Cell Struct Funct. 1996 Oct;21(5):381-5 [9118244.001]
  • [Cites] J Cell Biol. 1997 Jun 16;137(6):1393-401 [9182670.001]
  • [Cites] Mol Pathol. 1997 Dec;50(6):289-90 [9536277.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1603-8 [9990071.001]
  • [Cites] Oncogene. 1999 Jun 3;18(22):3376-82 [10362358.001]
  • [Cites] Int J Urol. 1999 May;6(5):240-4 [10375186.001]
  • [Cites] J Biol Chem. 1999 Aug 27;274(35):24579-84 [10455122.001]
  • [Cites] Eur J Cancer. 2004 Dec;40(18):2717-25 [15571953.001]
  • [Cites] Radiol Clin North Am. 2000 Jan;38(1):49-58 [10664666.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1671-6 [10749138.001]
  • [Cites] Genes Dev. 2000 Aug 1;14(15):1837-51 [10921899.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Oct;93(10):4135-40 [18647815.001]
  • (PMID = 19001380.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096534; United States / NCI NIH HHS / CA / CA96534
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / Membrane Proteins; 0 / Phosphoproteins; 0 / Receptors, Calcitonin; 0 / TJP1 protein, human; 0 / Zonula Occludens-1 Protein; 0 / beta Catenin; 9007-12-9 / Calcitonin; EC 2.7.11.26 / Glycogen Synthase Kinase 3
  • [Other-IDs] NLM/ PMC2613615
  •  go-up   go-down


57. Azevedo Rde S, Pires FR, Della Coletta R, de Almeida OP, Kowalski LP, Lopes MA: Oral myofibromas: report of two cases and review of clinical and histopathologic differential diagnosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Jun;105(6):e35-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myofibroma is a benign mesenchymal neoplasm composed of myofibroblasts which has been described with different synonyms since the first report in 1951.
  • Differential diagnosis included benign and malignant mesenchymal neoplasms, salivary gland tumors, and reactive processes.
  • Microscopic analysis of both lesions revealed a spindle cell tumor with immunoreactivity for vimentin, muscle-specific actin, and specific smooth muscle isoform alpha-actin, rendering the diagnoses of myofibroma.
  • Myofibroma presents a wide range of differential diagnosis, including benign and malignant neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417385.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Vimentin
  •  go-up   go-down


58. Czernobilsky B: Uterine tumors resembling ovarian sex cord tumors: an update. Int J Gynecol Pathol; 2008 Apr;27(2):229-35
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the former, the sex cord component constitutes a minor portion of an endometrial stromal neoplasm, whereas in the latter, it is the predominant or exclusive component of a uterine wall lesion composed of a variety of mesenchymal elements.
  • In group 1 tumors, the prognosis depends on the type, grade, and stage of the underlying stromal neoplasm.
  • Group 2 tumors seemed to be benign, although because of the occasional recurrence of these tumors, they should be considered of low-grade malignant potential.
  • Eventually, the abbreviation ESTSCLE, or endometrial stromal tumors with sex cord-like elements, was given to group 1 tumors, whereas UTROSCT, or uterine tumor resembling ovarian sex cord tumor, was used for group 2 tumors.
  • In conclusion, UTROSCT and, to a lesser degree, ESTSCLE, are polyphenotypic neoplasms, which, according to the evidence available at present, most likely arise from pluripotential uterine mesenchymal cells.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Differentiation. Diagnosis, Differential. Endometrial Stromal Tumors / diagnosis. Endometrial Stromal Tumors / pathology. Female. Humans

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317219.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 40
  •  go-up   go-down


59. Mentzel T, Schärer L, Kazakov DV, Michal M: Myxoid dermatofibrosarcoma protuberans: clinicopathologic, immunohistochemical, and molecular analysis of eight cases. Am J Dermatopathol; 2007 Oct;29(5):443-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dermatofibrosarcoma protuberans (DFSP) represents a locally aggressive mesenchymal neoplasm of skin and subcutis with characteristic clinicopathologic, immunohistochemical, and molecular findings.
  • In addition to typical cases, morphologic variants such as pigmented, fibrosarcomatous, myofibroblastic, and granular cell DFSP have been described.
  • Tumor size ranged from 1.5 to 12 cm.
  • Histologically, a nodular growth with peripheral diffuse infiltration, as well as a diffusely infiltrating growth of relatively uniform spindled and stellated tumor cells containing slightly enlarged nuclei, was noted.
  • Three cases were entirely myxoid, and in five cases more than 80% of the tumor area showed myxoid stromal changes.
  • In two cases each, focal fibrosarcomatous and focal giant cell fibroblastoma-like changes were present.
  • Scattered enlarged tumor cells were seen in two cases.
  • Immunohistochemically, tumor cells in all cases stained positively for CD34, and in one case each a focal expression of alpha-smooth muscle actin and epithelial membrane antigen (EMA) was noted.
  • In conclusion, myxoid DFSP represents a very rare morphologic variant with characteristic changes that has to be distinguished from benign and malignant myxoid mesenchymal neoplasms as superficial angiomyxoma, superficial acral fibromyxoma, myxoid solitary fibrous tumor, myxoid perineurioma, low-grade myxofibrosarcoma, low-grade fibromyxoid sarcoma, myxoid liposarcoma, and myxoid synovial sarcoma.
  • [MeSH-minor] Actins / metabolism. Adult. Aged. Antigens, CD34 / metabolism. Cell Proliferation. Collagen Type I / genetics. Collagen Type I / metabolism. Diagnosis, Differential. Female. Gene Fusion / genetics. Humans. Male. Middle Aged. Mucin-1 / metabolism. Proto-Oncogene Proteins c-sis / genetics. Proto-Oncogene Proteins c-sis / metabolism. Translocation, Genetic

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17890911.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD34; 0 / Collagen Type I; 0 / Mucin-1; 0 / Proto-Oncogene Proteins c-sis; 0 / collagen type I, alpha 1 chain
  •  go-up   go-down


60. Yuen HF, Chua CW, Chan YP, Wong YC, Wang X, Chan KW: Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer. Histopathology; 2007 Apr;50(5):648-58
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously found that up-regulation of TWIST, a highly conserved basic helix-loop-helix transcription factor, in prostatic cancer cells can promote epithelial to mesenchymal transition through down-regulation of E-cadherin.
  • METHODS AND RESULTS: TWIST and E-cadherin expression was studied in 115 prostatic cancer specimens, eight cases of prostatic intraepithelial neoplasia and 37 cases of benign prostatic hyperplasia by immunohistochemistry.
  • [MeSH-major] Adenocarcinoma / metabolism. Cadherins / metabolism. Nuclear Proteins / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Neoplasms / metabolism. Twist Transcription Factor / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cytoplasm / metabolism. Disease Progression. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Tissue Array Analysis. Up-Regulation


61. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS: Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn; 2005 Aug;7(3):413-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both benign and malignant tumors represent heterogenous tissue containing tumor cells and non-neoplastic mesenchymal and inflammatory cells.
  • We designed our Pyrosequencing assay for use with whole-genome-amplified DNA from paraffin-embedded tissue.
  • Assessing various mixtures of DNA from mutant KRAS cell lines and DNA from a wild-type KRAS cell line, we found that mutation detection rates for Pyrosequencing were superior to dideoxy sequencing.
  • In addition, Pyrosequencing proved superior to dideoxy sequencing in the detection of KRAS mutations from DNA mixtures of paraffin-embedded colon cancer and normal tissue as well as from paraffin-embedded pancreatic cancers.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Biol. 2001 Mar;8(3):243-52 [11306349.001]
  • [Cites] Clin Chem. 2002 Mar;48(3):428-35 [11861435.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Mar;11(3):227-34 [11895870.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5261-6 [11959976.001]
  • [Cites] Hum Mutat. 2002 May;19(5):479-85 [11968080.001]
  • [Cites] J Mol Diagn. 2002 Nov;4(4):185-90 [12411585.001]
  • [Cites] Clin Chem. 2002 Dec;48(12):2164-70 [12446472.001]
  • [Cites] Electrophoresis. 2002 Dec;23(24):4072-9 [12481262.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):146-50 [12866414.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):152-6 [12866415.001]
  • [Cites] J Mol Diagn. 2003 Nov;5(4):243-9 [14573784.001]
  • [Cites] Mol Biotechnol. 2004 Feb;26(2):147-64 [14764940.001]
  • [Cites] Nucleic Acids Res. 2004;32(5):e53 [15037663.001]
  • [Cites] Hum Mutat. 2004 May;23(5):406-12 [15108270.001]
  • [Cites] Hum Mutat. 2004 May;23(5):437-41 [15108274.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:250-6 [15251969.001]
  • [Cites] J Mol Diagn. 2004 Aug;6(3):236-42 [15269301.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5847-51 [1631067.001]
  • [Cites] Biotechniques. 1994 May;16(5):938-43 [8068351.001]
  • [Cites] J Clin Pathol. 1994 Dec;47(12):1082-4 [7876379.001]
  • [Cites] J Pathol. 1996 Jul;179(3):254-9 [8774479.001]
  • [Cites] Clin Chem. 1996 Sep;42(9):1382-90 [8787693.001]
  • [Cites] Diagn Mol Pathol. 1996 Dec;5(4):260-4 [8955617.001]
  • [Cites] Anal Biochem. 1997 May 1;247(2):394-403 [9177704.001]
  • [Cites] J Immunol Methods. 1997 Aug 7;206(1-2):11-9 [9328563.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):373-9 [9708798.001]
  • [Cites] Curr Opin Biotechnol. 1998 Dec;9(6):602-8 [9889145.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):83-95 [9916922.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9236-41 [10430926.001]
  • [Cites] Biotechniques. 2000 Jan;28(1):140-4, 146-7 [10649785.001]
  • [Cites] Gene. 2000 Aug 8;253(2):249-57 [10940563.001]
  • [Cites] Clin Chem. 2000 Dec;46(12):1929-38 [11106325.001]
  • [Cites] Genome Res. 2001 Jan;11(1):3-11 [11156611.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):105-10 [15681481.001]
  • (PMID = 16049314.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] ENG
  • [Grant] United States / PHS HHS / / P01-9467802; United States / PHS HHS / / P01-9483703; United States / PHS HHS / / R01-9485602
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC1867544
  •  go-up   go-down


62. Leunen M, Goossens A, Bourgain C, De Sutter P, Michielsen D, Amy JJ: A persistently recurring peri-urethral soft tissue lesion of the vulva. Pathol Res Pract; 2005;201(1):61-4
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A persistently recurring peri-urethral soft tissue lesion of the vulva.
  • Various mesenchymal lesions, some of which have only recently been characterized, may affect the vulva.
  • Clinically, benign lesions and tumor-like conditions may mimic a malignant process because of hypercellularity, mitotic activity, and rapid growth.
  • The biopsy showed spindle cell proliferation in a loose myxoid stroma with granulation tissue and a mixed inflammatory infiltrate.
  • Based on histology and immunohistochemistry, the initial diagnosis was that of a benign lesion.
  • [MeSH-major] Soft Tissue Neoplasms / metabolism. Soft Tissue Neoplasms / pathology. Urethra. Vulvar Neoplasms / metabolism. Vulvar Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry / methods. Neoplasm Recurrence, Local. Pregnancy. Staining and Labeling

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15807313.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


63. Vujanić GM, Kelsey A, Perlman EJ, Sandstedt B, Beckwith JB: Anaplastic sarcoma of the kidney: a clinicopathologic study of 20 cases of a new entity with polyphenotypic features. Am J Surg Pathol; 2007 Oct;31(10):1459-68
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report 20 cases of a distinct, previously unrecognized renal neoplasm, anaplastic sarcoma of the kidney with polyphenotypic features.
  • The tumors were identified by re-reviewing tumors with unusual anaplastic features from the National Wilms Tumor Study Pathology Center, the International Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group trials.
  • Histologically, all tumors showed a spindle cell component which contained either multiple foci or diffuse, widespread anaplastic changes with bizarre pleomorphic cells and very atypical mitotic figures.
  • The nodules of cartilage showed both benign and malignant features, often within the same tumor.
  • Cytokeratin, using the antibody CAM5.2, was uniformly negative within the tumor cells.
  • Tumor stage was known in 15 patients including 7 stage I, 4 stage II, 3 stage III, and 1 stage IV tumors.
  • One patient with stage I tumor developed widespread metastases and died.
  • Five stage I patients were alive and free of tumor at last follow-up.
  • In the differential diagnosis, anaplastic Wilms tumor, primary renal synovial sarcoma, malignant mesenchymoma, ectomesenchymoma, and mesenchymal chondrosarcomas have been considered but none of these tumors shared the same features as the 20 cases described here which represent a distinct clinicopathologic entity with morphologic features of a polyphenotypic anaplastic sarcoma of the kidney.
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Child. Child, Preschool. Desmin / analysis. Disease-Free Survival. Female. Gene Expression. Humans. Immunoenzyme Techniques. Infant. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Nephrectomy. Oncogene Proteins, Fusion / genetics. Oncogene Proteins, Fusion / metabolism. Phenotype. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Vimentin / analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17895746.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Desmin; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / SYT-SSX fusion protein; 0 / Vimentin
  •  go-up   go-down


64. Riddle ND, Yamauchi H, Caracciolo JT, Cheong D, Khakpour N, Bui MM: Giant cell tumor of the anterior rib masquerading as a breast mass: a case report and review of current literature. Cases J; 2010;3:51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the anterior rib masquerading as a breast mass: a case report and review of current literature.
  • INTRODUCTION: Giant cell tumor (GCT) is an aggressive, but usually benign bone neoplasm most commonly arising in the metaphysis/epiphyses of long bones.
  • While they are categorized as benign tumors, they can be locally aggressive and clinically have metastatic potential.
  • The most common locations of this tumor include the distal femur, proximal tibia, and distal radius.
  • Further evaluation revealed the mass to be an expansile rib lesion with extraosseous soft tissue invasion.
  • CONCLUSION: The histological features of bland mononuclear and multinucleated giant cells along with the lack of any additional mesenchymal elements led to the diagnosis of giant cell tumor.
  • Resection of tumor was performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skeletal Radiol. 1992;21(7):482-8 [1439904.001]
  • [Cites] Respir Med. 1991 Sep;85(5):435-6 [1759012.001]
  • [Cites] J Surg Oncol. 1989 Feb;40(2):128-31 [2492623.001]
  • [Cites] Intern Med. 2007;46(14):1151-2 [17634719.001]
  • [Cites] Skeletal Radiol. 2003 Feb;32(2):107-10 [12589492.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Jun;20(4):351-5 [12746169.001]
  • [Cites] Arch Orthop Trauma Surg. 2000;120(3-4):231-2 [10738893.001]
  • (PMID = 20205847.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2825505
  •  go-up   go-down


65. Fruth K, Hansen T, Katenkamp D, Mann W, Lippert BM: Recurrence of a laryngeal spindle cell sarcoma with a transformation into a higher grade of malignancy. Auris Nasus Larynx; 2009 Aug;36(4):491-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of a laryngeal spindle cell sarcoma with a transformation into a higher grade of malignancy.
  • Primary malignant mesenchymal neoplasms of the larynx are rare.
  • Sarcomas of the larynx account for <1% of all malignant laryngeal mesenchymal neoplasms.
  • This report examines a case of a recurring laryngeal, initial benign-appearing mesenchymal tumour, which first changed its clinical phenotype without any histological signs of malignancy and later also its histological appearance with signs of malignancy.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / surgery. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Sarcoma / pathology. Sarcoma / surgery

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19121902.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


66. Misago N, Mori T, Narisawa Y: Nestin expression in stromal cells of trichoblastoma and basal cell carcinoma. J Eur Acad Dermatol Venereol; 2010 Nov;24(11):1354-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin expression in stromal cells of trichoblastoma and basal cell carcinoma.
  • BACKGROUND: Both trichoblastoma and basal cell carcinoma (BCC) are considered to be a benign and malignant neoplasm of follicular germinative cells respectively.
  • A recent investigation revealed that the mesenchymal cells in the perifollicular sheath and evolving follicular papilla of embryonic hair germs and those cells in hair follicles in early anagen express nestin.
  • OBJECTIVE: The aim of the present study was to investigate whether trichoblastoma and BCC recapitulate the epithelial–mesenchymal interactions in embryonic hair germs or early anagen hair follicles by expressing nestin in stromal cells.
  • CONCLUSIONS: The development of trichoblastomas incompletely recapitulates the epithelial–mesenchymal interactions in embryonic hair germs or early anagen hair follicles, whereas BCCs fundamentally have lost this ability.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Intermediate Filament Proteins / metabolism. Nerve Tissue Proteins / metabolism. Sebaceous Gland Neoplasms / metabolism. Skin Neoplasms / metabolism. Stromal Cells / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20337823.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


67. Strzelczyk JM, Durczynski A, Szymanski D, Jablkowski M, Dworniak D, Sporny S: Primary perivascular epithelioid cell tumor (PEComa) of the liver: report of a case. Surg Today; 2009;39(10):916-21
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary perivascular epithelioid cell tumor (PEComa) of the liver: report of a case.
  • PEComa is very rare mesenchymal neoplasm which is formed by perivascular epithelioid cells and is characterized by dual melanocytic and myoid differentiation.
  • We herein present a patient who underwent a right hemihepatectomy for a huge tumor which could not be identified by imaging investigations.
  • A final histopathologic examination revealed a benign epithelioid tumor with a solid growth pattern, abundant vascularity, and frequently dilated vascular channels.
  • Immunohistochemically, the tumor cells were strongly positive for HMB-45, moderately positive for actin, and faintly positive for S-100, respectively.
  • Based on the above findings, a diagnosis of a primary clear cell "sugar" tumor was established.
  • Immunohistochemical findings play a crucial role in avoiding a misdiagnosis, and a surgical resection with an adequate margin of healthy tissue remains the gold standard of treatment.
  • [MeSH-major] Liver Neoplasms / pathology. Perivascular Epithelioid Cell Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2007 Nov 7;13(41):5537-9 [17907305.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):307-8 [1599021.001]
  • [Cites] Hum Pathol. 1991 Jul;22(7):727-8 [2071116.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1558-75 [16327428.001]
  • [Cites] Arch Pathol Lab Med. 2006 Aug;130(8):1219-22 [16879028.001]
  • [Cites] Surg Today. 2007;37(9):811-6 [17713740.001]
  • [Cites] Pathology. 1991 Jul;23(3):185-8 [1664078.001]
  • [Cites] Am J Surg Pathol. 1993 Nov;17(11):1092-102 [8214254.001]
  • [Cites] Ultrastruct Pathol. 1991 Jul-Oct;15(4-5):563-71 [1755113.001]
  • [Cites] Virchows Arch. 2008 Feb;452(2):119-32 [18080139.001]
  • [Cites] Am J Surg Pathol. 1991 Feb;15(2):199-202 [2025321.001]
  • [Cites] Arch Pathol Lab Med. 1991 Oct;115(10):1034-8 [1898230.001]
  • [Cites] Histopathology. 2000 May;36(5):443-50 [10792486.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Dec;27(12):681-4 [16344678.001]
  • [Cites] APMIS. 2007 Dec;115(12):1454-9 [18184420.001]
  • [Cites] Am J Surg Pathol. 1991 Jul;15(7):644-53 [1711793.001]
  • [Cites] World J Gastroenterol. 2008 Feb 7;14 (5):800-2 [18205275.001]
  • [Cites] Yale J Biol Med. 1971 Feb-Apr;43(4-5):213-22 [5578741.001]
  • [Cites] Cesk Patol. 2007 Jan;43(1):18-22 [17370472.001]
  • [Cites] Ann Chir. 2006 May;131(5):338-41 [16386232.001]
  • [Cites] BMC Urol. 2006 Aug 22;6:20 [16925812.001]
  • [Cites] J Pathol. 2008 Feb;214(3):387-93 [18085521.001]
  • [Cites] Hum Pathol. 2006 May;37(5):606-12 [16647959.001]
  • (PMID = 19784736.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 24
  •  go-up   go-down


68. Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, Gervaz P, Ruiz i Altaba A: Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med; 2009 Sep;1(6-7):338-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion.
  • Human colon cancers often start as benign adenomas through loss of APC, leading to enhanced beta CATENIN (beta CAT)/TCF function.
  • We show that the growth of CC xenografts, their recurrence and metastases require HH-GLI function, which induces a robust epithelial-to-mesenchymal transition (EMT).
  • Moreover, using a novel tumour cell competition assay we show that the self-renewal of CC stem cells in vivo relies on HH-GLI activity.
  • Our results indicate a key and essential role of the HH-GLI1 pathway in promoting CC growth, stem cell self-renewal and metastatic behavior in advanced cancers.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cells, Cultured. Gene Expression Regulation, Neoplastic. Humans. Mice. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Signal Transduction / drug effects. Veratrum Alkaloids / therapeutic use

  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2006 Feb 20;233(1):117-23 [16473672.001]
  • [Cites] Virchows Arch. 2009 Apr;454(4):369-79 [19280222.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] Development. 2001 Dec;128(24):5201-12 [11748155.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Development. 2004 Jan;131(2):337-45 [14681189.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):277-82 [14770182.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):831-7 [15170664.001]
  • [Cites] J Pathol. 2004 Aug;203(4):909-17 [15258993.001]
  • [Cites] Dev Biol. 2004 Sep 15;273(2):257-75 [15328011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Teratology. 1970 May;3(2):175-80 [4986632.001]
  • [Cites] Lipids. 1978 Oct;13(10):708-15 [723484.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] Nature. 1997 Oct 23;389(6653):876-81 [9349822.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Development. 1998 Sep;125(18):3553-62 [9716521.001]
  • [Cites] Development. 1999 Jun;126(14):3205-16 [10375510.001]
  • [Cites] Development. 2005 Jan;132(2):279-89 [15590741.001]
  • [Cites] Mech Dev. 2005 Feb;122(2):223-30 [15652709.001]
  • [Cites] Oncogene. 2006 Jan 26;25(4):609-21 [16158046.001]
  • [Cites] Gastroenterology. 2009 Jun;136(7):2187-2194.e1 [19324043.001]
  • [Cites] Surgery. 2006 May;139(5):665-70 [16701100.001]
  • [Cites] Gut. 2006 Jul;55(7):991-9 [16299030.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] J Gastroenterol. 2006 Dec;41(12):1238-9 [17287906.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5895-900 [17392427.001]
  • [Cites] World J Gastroenterol. 2007 Mar 21;13(11):1659-65 [17461467.001]
  • [Cites] Trends Cell Biol. 2007 Sep;17(9):438-47 [17845852.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2622-7 [17683069.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):638-48 [17932721.001]
  • [Cites] Cell Stem Cell. 2007 Oct 11;1(4):389-402 [18371377.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13427-32 [18765800.001]
  • [Cites] Nature. 2008 Sep 18;455(7211):406-10 [18754008.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):281-3 [18835029.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):603-7 [19092805.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4254-9 [19246386.001]
  • [Cites] EMBO J. 2009 Mar 18;28(6):663-76 [19214186.001]
  • [CommentIn] EMBO Mol Med. 2010 Oct;2(10):385-6; author reply 386-7 [20721989.001]
  • [CommentIn] EMBO Mol Med. 2009 Sep;1(6-7):300-2 [20049733.001]
  • (PMID = 20049737.001).
  • [ISSN] 1757-4684
  • [Journal-full-title] EMBO molecular medicine
  • [ISO-abbreviation] EMBO Mol Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Transcription Factors; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ PMC3378144
  •  go-up   go-down


69. Petrolla AA, Xin W: Hepatic angiomyolipoma. Arch Pathol Lab Med; 2008 Oct;132(10):1679-82
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for hepatic angiomyolipoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatic angiomyolipoma is a rare, benign, hepatic mesenchymal neoplasm found in both males and females, and most commonly in adult females.
  • Hepatic angiomyolipomas are composed of varying amounts of smooth muscle cells, adipose tissue, and vessels.
  • The smooth muscle cell component is the most specific to the diagnosis.
  • The differential diagnosis includes hepatocellular carcinoma, hepatic adenoma, leiomyoma, hepatoblastoma, melanoma, and gastrointestinal stromal tumor.
  • The immunohistochemical staining pattern differentiates this lesion from other malignant and benign liver lesions.
  • [MeSH-minor] Antigens, Neoplasm / metabolism. Female. Humans. MART-1 Antigen. Male. Melanoma-Specific Antigens. Neoplasm Proteins / metabolism. S100 Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18834230.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  • [Number-of-references] 17
  •  go-up   go-down


70. Lee YS, Dutta A: The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev; 2007 May 1;21(9):1025-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tumor suppressor microRNA let-7 represses the HMGA2 oncogene.
  • HMGA2, a high-mobility group protein, is oncogenic in a variety of tumors, including benign mesenchymal tumors and lung cancers.
  • Ectopic expression of let-7 reduced HMGA2 and cell proliferation in a lung cancer cell.
  • Our results provide a novel example of suppression of an oncogene by a tumor-suppressive miRNA and suggest that some tumors activate the oncogene through chromosomal translocations that eliminate the oncogene's 3'UTR with the let-7 target sites.

  • COS Scholar Universe. author profiles.
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Bioinformatics. 2004 Sep 28;5:139 [15453917.001]
  • [Cites] Exp Cell Res. 1989 Oct;184(2):538-45 [2806403.001]
  • [Cites] Mol Cell Biol. 1995 Mar;15(3):1545-53 [7862147.001]
  • [Cites] Nature. 1995 Aug 31;376(6543):771-4 [7651535.001]
  • [Cites] Nat Genet. 1995 Aug;10(4):436-44 [7670494.001]
  • [Cites] Am J Pathol. 1996 Sep;149(3):775-9 [8780382.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Aug;90(1):88-90 [8780755.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Jun;95(2):198-205 [9169041.001]
  • [Cites] Oncogene. 1997 Jun 19;14(24):2935-41 [9205100.001]
  • [Cites] Oncogene. 1999 Sep 9;18(36):5076-87 [10490844.001]
  • [Cites] Leukemia. 2005 Feb;19(2):245-52 [15618963.001]
  • [Cites] J Cell Biol. 2006 Aug 28;174(5):677-87 [16923828.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jan;8(1):9-22 [17183357.001]
  • [Cites] Mol Cancer. 2007;6:5 [17222355.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Apr;46(4):336-47 [17243163.001]
  • [Cites] Science. 2007 Mar 16;315(5818):1576-9 [17322030.001]
  • [Cites] Nature. 2000 Feb 24;403(6772):901-6 [10706289.001]
  • [Cites] Science. 2001 Aug 3;293(5531):834-8 [11452083.001]
  • [Cites] Oncogene. 2001 Jul 27;20(33):4537-41 [11494149.001]
  • [Cites] Carcinogenesis. 2001 Oct;22(10):1583-91 [11576996.001]
  • [Cites] Gene. 2001 Oct 17;277(1-2):63-81 [11602345.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2056-60 [12154197.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1351-8 [12649198.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jun;143(2):160-8 [12781451.001]
  • [Cites] Nature. 2003 Sep 25;425(6956):415-9 [14508493.001]
  • [Cites] Genes Dev. 2004 Mar 1;18(5):504-11 [15014042.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] Cell. 2005 Mar 11;120(5):623-34 [15766526.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] J Biol Chem. 2005 Apr 29;280(17):16635-41 [15722555.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):855-8 [16133369.001]
  • [Cites] J Pathol. 2006 Jun;209(2):206-12 [16521118.001]
  • [Cites] Curr Opin Investig Drugs. 2006 Jun;7(6):560-4 [16784027.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7453-9 [16885341.001]
  • [CommentIn] Genes Dev. 2007 May 1;21(9):1005-9 [17473167.001]
  • (PMID = 17437991.001).
  • [ISSN] 0890-9369
  • [Journal-full-title] Genes & development
  • [ISO-abbreviation] Genes Dev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA089406-06; United States / NCI NIH HHS / CA / R01 CA089406; United States / NCI NIH HHS / CA / R01 CA089406-06
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / HMGA2 Protein; 0 / MicroRNAs; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.1.26.3 / Ribonuclease III
  • [Other-IDs] NLM/ PMC1855228
  •  go-up   go-down


71. Bajaj MS, Pushker N, Kashyap S, Sen S, Vengayil S, Chaturvedi A: Fibrous histiocytoma of the lacrimal gland. Ophthal Plast Reconstr Surg; 2007 Mar-Apr;23(2):145-7
MedlinePlus Health Information. consumer health - Tears.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibrous histiocytoma, a primary mesenchymal tumor of the orbit, is known to arise from various ocular and adnexal tissues.
  • We are unable to find a published report of this tumor originating from the lacrimal gland.
  • We report a case of a benign fibrous histiocytoma of the lacrimal gland in an 11 year old girl who presented with painless, progressive eyelid swelling and mild proptosis.
  • The tumor was completely excised by anterolateral orbitotomy.
  • Light microscopy showed a spindle cell tumor arising from the lacrimal gland.
  • The tumor cells were arranged in a characteristic storiform (cartwheel) pattern with no pleomorphism or mitotic figures.
  • Immunohistochemically, the tumor cells were focally positive for CD-68 and negative for S-100, smooth muscle actin, vimentin, and CD-34, which ruled out neurofibroma, leiomyoma, solitary fibrous tumor, and hemangiopericytoma.
  • Based on these features, a diagnosis of benign fibrous histiocytoma was made.
  • [MeSH-major] Eye Neoplasms / pathology. Histiocytoma, Benign Fibrous / pathology. Lacrimal Apparatus Diseases / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Child. Female. Humans. Neoplasm Proteins / analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17413632.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


72. Chaplin A, Conrad DM, Tatlidil C, Jollimore J, Walsh N, Covert A, Pasternak S: Primary cutaneous PEComa. Am J Dermatopathol; 2010 May;32(3):310-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microscopic examination of the excisional specimen revealed a dermal tumor composed of nests of epithelioid cells exhibiting clear cytoplasm.
  • The tumor showed an infiltrative border.
  • Immunohistochemical evaluation revealed that the tumor cells were positive for HMB-45 and microftalmia associated transcription factor (MITF).
  • The tumor cells were negative for S-100 protein, alfa smooth muscle actin, HHF-35, and various cytokeratins.
  • Pecomas are rare, recently described mesenchymal tumors composed of perivascular epithelioid cells.
  • They constitute a spectrum of lesions in different organs including angiomyolipoma of the kidney and liver, sugar tumor of the lung, lymphangiomatosis, and lymphangiomyoma.
  • Follow-up data is limited but they appear to behave in a benign fashion.
  • We report an additional case with the goal of alerting dermatopathologists to this distinctive unusual neoplasm.
  • [MeSH-major] Perivascular Epithelioid Cell Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Biopsy. Desmin / analysis. Female. Humans. Leg. Melanoma-Specific Antigens. Microphthalmia-Associated Transcription Factor / analysis. Middle Aged. Neoplasm Proteins / analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139753.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Desmin; 0 / MITF protein, human; 0 / Melanoma-Specific Antigens; 0 / Microphthalmia-Associated Transcription Factor; 0 / Neoplasm Proteins
  •  go-up   go-down


73. Dobashi Y, Watanabe H, Matsubara M, Yanagawa T, Raz A, Shimamiya T, Ooi A: Autocrine motility factor/glucose-6-phosphate isomerase is a possible predictor of metastasis in bone and soft tissue tumours. J Pathol; 2006 Jan;208(1):44-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autocrine motility factor/glucose-6-phosphate isomerase is a possible predictor of metastasis in bone and soft tissue tumours.
  • In order to assess the involvement of autocrine motility factor (AMF) in mesenchymal tumours, AMF protein and mRNA expression was analysed in tumours, tumour-like lesions, and other lesions of bone and soft tissue.
  • Chordoid, chondroid, and muscular tumours revealed higher immunoreactivity in both benign and malignant tumours.
  • Generally, malignant tumours revealed higher expression of AMF than benign tumours of the same histopathological lineage, except for dermatofibroma/dermatofibrosarcoma protuberans.
  • This secreted AMF presumably enhances their cell motility through an autocrine effect and eventually causes increased metastatic potential.
  • Collectively, AMF was observed in a wide spectrum of lesions of mesenchymal tissue, supporting the notion that it is involved in various cellular functions, including proliferation, differentiation, metabolism, and metastasis.
  • [MeSH-major] Bone Neoplasms / metabolism. Glucose-6-Phosphate / metabolism. Glucose-6-Phosphate Isomerase / analysis. Soft Tissue Neoplasms / metabolism
  • [MeSH-minor] Cell Line, Tumor. Humans. Immunoblotting / methods. Immunohistochemistry / methods. Neoplasm Metastasis. Neoplasm Proteins / analysis. Proteasome Inhibitors. RNA, Messenger / analysis. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Pathological Society of Great Britain and Ireland.
  • (PMID = 16294294.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-51714
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Proteasome Inhibitors; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 56-73-5 / Glucose-6-Phosphate; EC 5.3.1.9 / Glucose-6-Phosphate Isomerase
  •  go-up   go-down


74. Rau T, Soeder S, Olk A, Aigner T: Parosteal lipoma of the thigh with cartilaginous and osseous differentiation: an osteochondrolipoma. Ann Diagn Pathol; 2006 Oct;10(5):279-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lipomas are very common benign soft tissue neoplasms.
  • Mature cartilage and bone arising in a lipoma is a rare event and is mostly associated with a parosteal localization of the neoplasm.
  • We describe a new case of osteochondrolipoma showing not only major adipocytic differentiation but also areas of fibrocytic and cartilaginous cell differentiation and bone formation (both endochondral and membranous).
  • The occurrence of at least 4 distinct directions of mesenchymal cell differentiation within a benign neoplasia underlines the concept of multilineage differentiation of pluripotent mesenchymal stem cells.
  • Such a multidirectional potential was recently well established in vitro in stem cells present in adult adipocytic tissue.
  • [MeSH-major] Bone and Bones / pathology. Cartilage / pathology. Lipoma / pathology. Periosteum / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adipocytes / pathology. Aged. Cell Differentiation. Cell Transformation, Neoplastic / pathology. Diagnosis, Differential. Humans. Male. Mesenchymal Stromal Cells / pathology. Ossification, Heterotopic / pathology. Thigh

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16979520.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


75. Horn LC, Dallacker M, Bilek K: [Carcinosarcomas (malignant mixed Mullerian tumors) of the uterus. Morphology, pathogenetic aspects and prognostic factors]. Pathologe; 2009 Jul;30(4):292-301
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant mixed Mullerian tumors (MMMT; carcinosarcomas) are rare epithelial-mesenchymal tumors.
  • With an overall survival rate of 30%-40% the prognosis is much worse compared to high grade endometrioid or serous/clear cell carcinomas.
  • Clinical, morphologic and molecular data suggest that MMMTs are really metaplastic carcinomas in which the mesenchymal part retains epithelial features.
  • The strongest prognostic factor is tumor stage followed by lymph node metastases, deep myometrial infiltration, involvement of the cervix and tumor size.
  • The main differential diagnoses include uterine sarcomas, adenosarcoma and benign metaplastic change within the endometrium.
  • [MeSH-minor] Carcinoma, Endometrioid / pathology. Cervix Uteri / pathology. Female. Humans. Immunohistochemistry / methods. Lymphatic Metastasis. Myometrium / pathology. Neoplasm Staging. Prognosis. Survival Rate. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2005 Dec;6(12):961-71 [16321764.001]
  • [Cites] Gynecol Oncol. 1997 Dec;67(3):316-21 [9441781.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(1):1-19 [2152890.001]
  • [Cites] Gynecol Oncol. 2005 Aug;98(2):274-80 [15972232.001]
  • [Cites] Cancer. 2000 Jun 15;88(12):2782-6 [10870061.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):684-7 [16797683.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4B):3069-74 [11712812.001]
  • [Cites] J Clin Pathol. 2002 May;55(5):321-5 [11986333.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):786-96 [14967435.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jan;22(1):75-82 [12496702.001]
  • (PMID = 19495763.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


76. Pawlicki J, Król R, Kajor M, Ziaja J: [Case of malignant tumour phyllodes converting to fibrosarcoma]. Pol Merkur Lekarski; 2007 Mar;22(129):215-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumour phyllodes is rare breast neoplasm.
  • Tumours phyllodes are composed of hypercellular mesenchymal stroma and epithelial elements.
  • They are commonly classified as benign, rarely as borderline or malignant.
  • [MeSH-major] Breast Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Fibrosarcoma / pathology. Neoplasm Recurrence, Local / pathology. Phyllodes Tumor / pathology

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17682679.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


77. Rajan KV, Santhi T: A case of solitary fibrous tumour of the nose and paranasal sinuses. Indian J Otolaryngol Head Neck Surg; 2006 Jul;58(3):316-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Solitary fibrous tumours (SFT), formerly known as benign fibrous mesothelioma, are rare mesenchymal spindle cell neoplasms, originally described in the pleura, but now found to arise in many other locations such as mediastinum, urogenital tract, face, nose, paranasal sinuses, orbit, meninges, ear, buccal mucosa, tongue, salivary gland etc.
  • It was first described as a distinct neoplasm in 1931 by Klemperer and Rabin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Diagn Pathol. 2003 Jun;7(3):169-73 [12808569.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Oct;17(9):1767-72 [8896635.001]
  • (PMID = 23120332.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3450392
  • [Keywords] NOTNLM ; Solitary fibrous tumour / paranasal sinuses
  •  go-up   go-down


78. Coco DP, Hirsch MS, Hornick JL: Smoothelin is a specific marker for smooth muscle neoplasms of the gastrointestinal tract. Am J Surg Pathol; 2009 Dec;33(12):1795-801
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This contrasts with other smooth muscle proteins (eg, h-caldesmon, alpha-smooth muscle actin, desmin, smooth muscle myosin), which are expressed in proliferative (early) stages of smooth muscle development and occasionally in other cell types (striated muscle, myofibroblasts, myoepithelial cells, pericytes).
  • Smoothelin expression in mesenchymal tumors of the gastrointestinal (GI) tract has not been evaluated earlier.
  • A total of 150 mesenchymal neoplasms of the GI tract, abdominal cavity, and retroperitoneum were retrieved from consult and surgical pathology archives, including 54 GISTs (8 KIT-negative; 13 desmin-positive), 17 GI leiomyosarcomas (LMS), 11 GI mural leiomyomas, 13 leiomyomas of the muscularis mucosae, 12 gastric schwannomas, 15 inflammatory myofibroblastic tumors, 9 cases of mesenteric desmoid fibromatosis, 10 dedifferentiated liposarcomas, and 9 malignant peripheral nerve sheath tumors.
  • Cytoplasmic expression of smoothelin was present in all 24 (100%) benign smooth muscle tumors (mural leiomyomas and leiomyomas of the muscularis mucosae).
  • Nuclear expression of smoothelin was not detected in any of the other tumor types examined.
  • In summary, diffuse cytoplasmic staining for smoothelin is highly sensitive and specific for benign leiomyomas of the GI tract.
  • These findings suggest that the extent and pattern of smoothelin expression may help differentiate between benign and malignant mesenchymal tumors of the GI tract, and may be useful in distinguishing leiomyomas from KIT-negative and/or desmin-positive GISTs.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cytoskeletal Proteins / analysis. Gastrointestinal Neoplasms / chemistry. Muscle Proteins / analysis. Smooth Muscle Tumor / chemistry
  • [MeSH-minor] Cell Differentiation. Cell Nucleus / chemistry. Cytoplasm / chemistry. Desmin / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Neoplasm Staging. Predictive Value of Tests. Proto-Oncogene Proteins c-kit / analysis. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950405.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Desmin; 0 / Muscle Proteins; 0 / SMTN protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


79. Koseoglu RD, Ozkan N, Filiz NO, Kayaoglu HA, Aydin M, Culha EN, Ersoy OF: Intranodal palisaded myofibroblastoma; a case report and review of the literature. Pathol Oncol Res; 2009 Jun;15(2):297-300
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intranodal palisaded myofibroblastoma (IPM) also called as intranodal hemorrhagic spindle cell tumor with amianthoid fibers is a distinctive and rare mesenchymal neoplasm of lymph nodes.
  • In contrast to Kaposi's sarcoma, it behaves in a benign fashion and does not need any further therapy except total surgical resection of the mass.
  • This neoplasm has a great predilection for the inguinal region.
  • We present a 43-year-old-male patient with IPM and discuss histological, immunohistochemical features and pathogenesis of this rare benign neoplasm.
  • [MeSH-major] Carcinoma / pathology. Lymph Nodes / pathology. Neoplasms, Muscle Tissue / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Humans. Immunoenzyme Techniques. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18991023.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 20
  •  go-up   go-down


80. Kambham N, Kong C, Longacre TA, Natkunam Y: Utility of syndecan-1 (CD138) expression in the diagnosis of undifferentiated malignant neoplasms: a tissue microarray study of 1,754 cases. Appl Immunohistochem Mol Morphol; 2005 Dec;13(4):304-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of syndecan-1 (CD138) expression in the diagnosis of undifferentiated malignant neoplasms: a tissue microarray study of 1,754 cases.
  • However, it has not been widely tested in non-hematolymphoid tissues, and thus its utility in the setting of an undifferentiated malignant neoplasm has not been evaluated.
  • The authors conducted an extensive study of CD138 staining in over 1,700 normal, benign, and malignant non-hematolymphoid tissues, using five tissue microarrays.
  • A small subset of mesenchymal neoplasms also showed membrane and cytoplasmic immunoreactivity.
  • In squamous cell carcinoma of the head and neck, renal cell carcinoma, and prostate adenocarcinoma, the intensity of CD138 staining inversely correlated with the histologic grade of the carcinoma.
  • These results indicate that CD138 immunoreactivity is widespread in normal and neoplastic epithelial tissues, as well as a variety of undifferentiated epithelial and mesenchymal processes.
  • The authors conclude that the expression of syndecan-1, although relatively specific to plasma cells within the hematolymphoid system, should be interpreted with extreme caution in the setting of an undifferentiated neoplasm.
  • Furthermore, the two commercially available monoclonal CD138 antibodies tested in this study showed significant differences in their immunoreactivity in different tumor types.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16280658.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Glycoproteins; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans
  •  go-up   go-down


81. Tischler V, Fritzsche FR, Wild PJ, Stephan C, Seifert HH, Riener MO, Hermanns T, Mortezavi A, Gerhardt J, Schraml P, Jung K, Moch H, Soltermann A, Kristiansen G: Periostin is up-regulated in high grade and high stage prostate cancer. BMC Cancer; 2010;10:273
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Expression of periostin is an indicator of epithelial-mesenchymal transition in cancer but a detailed analysis of periostin expression in prostate cancer has not been conducted so far.
  • Metastatic prostate cancers (n = 20), hormone refractory prostate cancers (n = 19) and benign prostatic tissues (n = 38) were also analyzed.
  • RESULTS: In total, strong epithelial periostin expression was detectable in 142 of 418 (34.0%) of prostate carcinomas and in 11 of 38 benign prostate glands (28.9%).
  • [MeSH-major] Biomarkers, Tumor / analysis. Cell Adhesion Molecules / analysis. Prostatic Neoplasms / chemistry
  • [MeSH-minor] Aged. Chi-Square Distribution. Cohort Studies. Epithelial Cells / chemistry. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prognosis. Prostate-Specific Antigen / analysis. Stromal Cells / chemistry. Time Factors. Up-Regulation

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biochem. 2002;86(4):792-804 [12210745.001]
  • [Cites] Mech Dev. 2001 May;103(1-2):183-8 [11335131.001]
  • [Cites] Jpn J Cancer Res. 2001 Aug;92(8):869-73 [11509119.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):843-8 [11550156.001]
  • [Cites] Cancer Lett. 2001 Oct 22;172(1):37-42 [11595127.001]
  • [Cites] J Pediatr Surg. 2002 Sep;37(9):1293-7 [12194119.001]
  • [Cites] Cell Tissue Res. 2003 Jun;312(3):345-51 [12761672.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):754-9 [12874078.001]
  • [Cites] Dev Dyn. 2004 Apr;229(4):857-68 [15042709.001]
  • [Cites] Mol Cell Biol. 2004 May;24(9):3992-4003 [15082792.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):329-39 [15093540.001]
  • [Cites] J Orthop Res. 2004 May;22(3):520-5 [15099630.001]
  • [Cites] J Appl Physiol (1985). 2004 Oct;97(4):1550-8; discussion 1549 [15121739.001]
  • [Cites] Biochem J. 1993 Aug 15;294 ( Pt 1):271-8 [8363580.001]
  • [Cites] J Bone Miner Res. 1999 Jul;14(7):1239-49 [10404027.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):77-83 [15514205.001]
  • [Cites] Anat Rec A Discov Mol Cell Evol Biol. 2005 Dec;287(2):1205-12 [16240445.001]
  • [Cites] Thyroid. 2006 Feb;16(2):161-75 [16676402.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):19700-8 [16702213.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6928-35 [16849536.001]
  • [Cites] Mol Cell Proteomics. 2006 Nov;5(11):2083-91 [16861259.001]
  • [Cites] Br J Cancer. 2006 Nov 20;95(10):1396-403 [17060937.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jan;101(1):83-93 [16807673.001]
  • [Cites] Oncogene. 2007 Mar 29;26(14):2082-94 [17043657.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1447-64 [17408641.001]
  • [Cites] Histol Histopathol. 2007 Oct;22(10):1167-74 [17616943.001]
  • [Cites] J Cell Physiol. 2007 Nov;213(2):374-83 [17680632.001]
  • [Cites] World J Gastroenterol. 2007 Oct 21;13(39):5261-6 [17876898.001]
  • [Cites] Int J Urol. 2007 Nov;14(11):1034-9 [17956532.001]
  • [Cites] Br J Cancer. 2008 Feb 12;98(3):604-10 [18212746.001]
  • [Cites] J Exp Med. 2008 Feb 18;205(2):295-303 [18208976.001]
  • [Cites] J Clin Pathol. 2008 Apr;61(4):494-8 [17938160.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2479-88 [18381457.001]
  • [Cites] Int J Cancer. 2008 Jun 15;122(12):2707-18 [18381746.001]
  • [Cites] Cancer. 2008 Apr 25;114(2):124-33 [18327805.001]
  • [Cites] J Endocrinol. 2008 May;197(2):401-8 [18434370.001]
  • [Cites] Stem Cells. 2008 Jun;26(6):1425-35 [18403754.001]
  • [Cites] J Histochem Cytochem. 2008 Aug;56(8):753-64 [18443362.001]
  • [Cites] Mod Pathol. 2008 Aug;21(8):1044-53 [18487994.001]
  • [Cites] Eur Urol. 2008 Nov;54(5):1097-106 [18061337.001]
  • [Cites] Clin Cancer Res. 2008 Nov 15;14(22):7430-7 [19010860.001]
  • [Cites] Prostate. 2009 Sep 15;69(13):1398-403 [19479898.001]
  • [Cites] Histopathology. 2010 Apr;56(5):600-6 [20459570.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5358-64 [12235007.001]
  • (PMID = 20534149.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / POSTN protein, human; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ PMC2903527
  •  go-up   go-down


82. Soldano AC, Meehan SA: Cutaneous solitary fibrous tumor: a report of 2 cases and review of the literature. Am J Dermatopathol; 2008 Feb;30(1):54-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous solitary fibrous tumor: a report of 2 cases and review of the literature.
  • Solitary fibrous tumor is an uncommon mesenchymal neoplasm that can arise in both pleural and extrapleural locations.
  • Composed of spindled cells intimately admixed with collagen bundles arranged in a "patternless pattern," this heterogeneous tumor can mimic a variety of benign and malignant mesenchymal neoplasms.
  • Although solitary fibrous tumors in cutaneous and subcutaneous regions are extremely rare, it should be considered in the differential diagnosis of primary spindle cell neoplasms of the skin.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212546.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Pereira PD, Lopes CC, Matos AJ, Cortez PP, Gärtner F, Medeiros R, Lopes C: Caveolin-1 in diagnosis and prognosis of canine mammary tumours: comparison of evaluation systems. J Comp Pathol; 2010 Aug-Oct;143(2-3):87-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In recent years there has been some controversy regarding the distribution of Cav-1 in normal and neoplastic mammary cell types, which may be attributed to different scoring systems adopted in different studies.
  • Results obtained with both scoring methods were similar, revealing absence of immunoreactivity in normal luminal epithelium and in benign neoplasms and clearly associating Cav-1 expression with malignant transformation.
  • The data suggest that Cav-1 expression is associated with highly malignant subtypes of mammary tumours (i.e. basal-like carcinoma), invasion and metastasis, thus supporting the hypothesis that it may play a major role in the epithelial-mesenchymal transition process.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma / veterinary. Caveolin 1 / metabolism. Dog Diseases / diagnosis. Mammary Glands, Animal / metabolism. Mammary Neoplasms, Animal / diagnosis
  • [MeSH-minor] Animals. Caveolae / metabolism. Dogs. Female. Immunohistochemistry. Neoplasm Invasiveness. Neoplasm Metastasis. Prognosis. Research Design. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20153868.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Caveolin 1
  •  go-up   go-down


84. Kim E, Bae TS, Kwon Y, Kim TH, Chung KW, Kim SW, Ro J, Lee ES: Primary malignant teratoma with a primitive neuroectodermal tumor component in thyroid gland: a case report. J Korean Med Sci; 2007 Jun;22(3):568-71
Genetic Alliance. consumer health - Teratoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant teratoma with a primitive neuroectodermal tumor component in thyroid gland: a case report.
  • Teratomas comprise the most common extragonadal germ cell tumors in childhood.
  • Most teratomas involving the thyroid are benign and occur in children.
  • Pathologic examination revealed it to be malignant teratoma composed of primitive neuroepithelial tissue with primitive neural tubes and loose myxoid to fibrous immature mesenchymal stroma.
  • This is the first case, to our knowledge, of malignant thyroid teratoma with a exuberant primitive neuroectodermal tumor component in Korea.
  • [MeSH-minor] Adult. Female. Head and Neck Neoplasms / pathology. Humans. Neoplasm Metastasis. Positron-Emission Tomography / methods. Thyroid Diseases / diagnosis. Thyroidectomy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Mar 1;88(5):1149-58 [10699906.001]
  • [Cites] Am J Otolaryngol. 2000 Mar-Apr;21(2):112-5 [10758996.001]
  • [Cites] Acta Cytol. 2000 May-Jun;44(3):375-9 [10833994.001]
  • [Cites] Ann Diagn Pathol. 2001 Oct;5(5):285-92 [11598856.001]
  • [Cites] N Engl J Med. 2003 Feb 20;348(8):694-701 [12594313.001]
  • [Cites] Thyroid. 2003 Apr;13(4):401-4 [12804109.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):1015-22 [9818077.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2796-804 [7595741.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):896-904 [9255252.001]
  • [Cites] Am J Clin Oncol. 1998 Apr;21(2):212-4 [9537215.001]
  • [Cites] Ann Hematol. 1998 May;76(5):183-8 [9671130.001]
  • [Cites] Head Neck. 1998 Oct;20(7):649-53 [9744468.001]
  • [Cites] Bull Cancer. 1995;82 Suppl 1:56s-60s [7542945.001]
  • (PMID = 17596674.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2693658
  •  go-up   go-down


85. Engelman RW, Jackson RJ, Coppola D, Wharton W, Cantor AB, Pledger WJ: Loss of nuclear p21(Cip1/WAF1) during neoplastic progression to metastasis in gamma-irradiated p21 hemizygous mice. Exp Mol Pathol; 2007 Jun;82(3):234-44
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To evaluate the expression of p21 in tissues prone or resistant to tumorigenesis as a function of gamma-irradiation, and to determine whether phenotypic loss of p21 heterozygosity occurs during tumor progression in p21(+/-) mice, tissues and tumors from gamma-irradiated mice were evaluated immunohistochemically.
  • Benign tumors were more often p21-positive and comprised of larger subsets of nuclear p21-positive cells than were malignant tumors of the same histopathological type, while metastatic cancers were nuclear p21-negative (p=0.0003).
  • Mesenchymal tumors, though rare, were more likely metastatic than were epithelial tumors (p=0.0004), and these were invariably nuclear p21-negative.
  • In contrast, p21 did not localize to nuclei of cortical thymocytes, a tissue where tumorigenesis was not augmented by reduced p21 gene dosage.
  • Cellular subclones of malignant tumors, especially those of mesenchymal cell origin, which lack nuclear p21 may more readily acquire the genetic alterations of the metastatic phenotype.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1997 Apr 1;11(7):847-62 [9106657.001]
  • [Cites] Oncogene. 1999 Aug 19;18(33):4689-98 [10467416.001]
  • [Cites] Int J Cancer. 2000 Jan 20;89(1):14-8 [10719725.001]
  • [Cites] Adv Exp Med Biol. 1999;472:73-88 [10736618.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1113-8 [10741741.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):6147-58 [10913196.001]
  • [Cites] Biochim Biophys Acta. 2000 Jul 31;1471(1):M43-56 [10967424.001]
  • [Cites] Oncogene. 2000 Nov 9;19(47):5338-47 [11103935.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):565-9 [11212250.001]
  • [Cites] EMBO Rep. 2001 Jan;2(1):27-34 [11252720.001]
  • [Cites] Nat Cell Biol. 2001 Mar;3(3):245-52 [11231573.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6234-8 [11507077.001]
  • [Cites] Virchows Arch. 2001 Aug;439(2):132-40 [11561753.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2291-6 [11895758.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2077-84 [11929828.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):89-96 [12027580.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]
  • [Cites] Oncogene. 2002 Dec 5;21(55):8486-97 [12466968.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3021-5 [12810620.001]
  • [Cites] Oncogene. 2004 Aug 5;23(35):6006-11 [15195145.001]
  • [Cites] Science. 1977 Aug 26;197(4306):893-5 [887927.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):847-9 [8479522.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):849-52 [8479523.001]
  • [Cites] Cell. 1993 Nov 19;75(4):805-16 [8242751.001]
  • [Cites] Cell. 1993 Nov 19;75(4):817-25 [8242752.001]
  • [Cites] Nature. 1993 Dec 16;366(6456):701-4 [8259214.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):1815-23 [8114714.001]
  • [Cites] Radiother Oncol. 1994 Apr;31(1):1-13 [8041894.001]
  • [Cites] Oncogene. 1994 Nov;9(11):3389-96 [7936667.001]
  • [Cites] Oncogene. 1994 Nov;9(11):3397-406 [7936668.001]
  • [Cites] Blood. 1994 Dec 1;84(11):3781-4 [7949134.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1821-8 [7997877.001]
  • [Cites] Science. 1995 Feb 17;267(5200):1018-21 [7863327.001]
  • [Cites] Science. 1995 Feb 17;267(5200):1024-7 [7863329.001]
  • [Cites] Nature. 1995 Mar 9;374(6518):131-4 [7877684.001]
  • [Cites] Oncogene. 1995 Jun 15;10(12):2281-7 [7784076.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2910-9 [7796420.001]
  • [Cites] Cell. 1995 Aug 25;82(4):675-84 [7664346.001]
  • [Cites] Biochim Biophys Acta. 1995 Sep 19;1263(3):275-80 [7548219.001]
  • [Cites] Nature. 1995 Oct 12;377(6549):552-7 [7566157.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5187-90 [7585571.001]
  • [Cites] J Cell Biol. 1996 Feb;132(4):657-66 [8647896.001]
  • [Cites] Am J Pathol. 1996 Aug;149(2):381-7 [8701978.001]
  • [Cites] Biochem J. 1995 Jun 15;308 ( Pt 3):697-711 [8948422.001]
  • [Cites] Curr Opin Genet Dev. 1997 Feb;7(1):46-51 [9024633.001]
  • [Cites] Leuk Lymphoma. 1997 Jun;26(1-2):35-41 [9250785.001]
  • [Cites] Int J Cancer. 1997 Oct 21;74(5):529-34 [9355976.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14590-5 [9405657.001]
  • [Cites] J Cell Biol. 1998 Apr 20;141(2):503-14 [9548727.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1251-61 [9607584.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6791-6 [9618491.001]
  • [Cites] Mol Cell. 1998 Mar;1(4):553-63 [9660939.001]
  • [Cites] Genes Dev. 1999 Jan 15;13(2):213-24 [9925645.001]
  • [Cites] EMBO J. 1999 Mar 1;18(5):1223-34 [10064589.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2050-4 [10232585.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4167-78 [10361114.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9089-94 [10430900.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):262-5 [10667572.001]
  • (PMID = 17207793.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA67360; United States / NCI NIH HHS / CA / P01 CA078038-040004; United States / NCI NIH HHS / CA / CA078038-040004; United States / NCI NIH HHS / CA / CA067360-09; United States / NCI NIH HHS / CA / R01 CA067360-09; United States / NCI NIH HHS / CA / R01 CA067360; United States / NCI NIH HHS / CA / CA78038
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Ki-67 Antigen
  • [Other-IDs] NLM/ NIHMS24071; NLM/ PMC2039892
  •  go-up   go-down


86. Heffernan EJ, Hayes MM, Alkubaidan FO, Clarkson PW, Munk PL: Aggressive angiomyxoma of the thigh. Skeletal Radiol; 2008 Jul;37(7):673-8
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While benign, the tumour is locally infiltrative and consequently has a high rate of local recurrence following surgery; therefore, accurate pre-operative diagnosis is important.
  • The characteristic location of these tumours in the low pelvis or perineum has led to speculation that aggressive angiomyxomas arise from a mesenchymal cell that is unique to the perineum.
  • We describe a case of aggressive angiomyxoma arising in the thigh of a 54-year-old man, which we believe is the first reported instance of this rare neoplasm occurring remote from the pelvis or perineum in a male patient.
  • [MeSH-major] Magnetic Resonance Imaging. Myxoma / diagnosis. Soft Tissue Neoplasms / diagnosis. Thigh / diagnostic imaging. Thigh / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2003 Sep;29(7):559-63 [12943618.001]
  • [Cites] Int J Gynecol Cancer. 2005 Jan-Feb;15(1):140-5 [15670309.001]
  • [Cites] J Gastroenterol. 2002;37(4):303-8 [11993516.001]
  • [Cites] AJR Am J Roentgenol. 1999 Feb;172(2):435-8 [9930798.001]
  • [Cites] J Clin Pathol. 2000 Aug;53(8):603-5 [11002763.001]
  • [Cites] Int J Urol. 2004 Jun;11(6):432-5 [15157218.001]
  • [Cites] Am J Clin Pathol. 1997 Jan;107(1):45-51 [8980366.001]
  • [Cites] Hum Pathol. 1985 Jun;16(6):621-8 [3997139.001]
  • [Cites] Ann Diagn Pathol. 2006 Aug;10(4):197-204 [16844560.001]
  • [Cites] N Engl J Med. 1999 Dec 2;341(23):1772 [10610453.001]
  • [Cites] Clin Radiol. 2003 Feb;58(2):157-62 [12623047.001]
  • [Cites] Urol Int. 1997;58(4):247-9 [9253128.001]
  • [Cites] AJR Am J Roentgenol. 1998 Aug;171(2):530-1 [9694499.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):396-401 [16445665.001]
  • [Cites] Int J Colorectal Dis. 2007 Dec;22(12):1545-6 [17242939.001]
  • [Cites] Radiology. 2007 Feb;242(2):625-7 [17255431.001]
  • [Cites] Abdom Imaging. 2006 May-Jun;31(3):383-6 [16317491.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):1072-4 [14608546.001]
  • [Cites] J Oral Maxillofac Surg. 2004 Nov;62(11):1429-31 [15510368.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:356-60 [16515622.001]
  • [Cites] Am J Surg Pathol. 1983 Jul;7(5):463-75 [6684403.001]
  • [Cites] Ultrastruct Pathol. 2006 May-Jun;30(3):193-205 [16825121.001]
  • [Cites] J Clin Ultrasound. 2001 Oct;29(8):476-8 [11745856.001]
  • [Cites] Histopathology. 1997 Jan;30(1):3-10 [9023551.001]
  • [Cites] Cancer. 1996 Jul 1;78(1):79-90 [8646730.001]
  • (PMID = 18338163.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


87. Ma L, Kowalski D, Javed K, Hui P: Atypical angiomyolipoma of kidney in a patient with tuberous sclerosis: a case report with p53 gene mutation analysis. Arch Pathol Lab Med; 2005 May;129(5):676-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiomyolipoma (AML) is the most common benign mesenchymal tumor of the kidney.
  • It belongs to the family of perivascular epithelioid cell tumors and is typically composed of blood vessels, adipose tissue, and smooth muscle- like cells, which are characteristically positive for HMB-45.
  • The tumor consisted of mostly epithelioid cells with marked nuclear pleomorphism and frequent mitoses and was positive for HMB-45.
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Cytoplasm / ultrastructure. DNA Mutational Analysis. DNA, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Intercellular Junctions / ultrastructure. Nephrectomy. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Treatment Outcome

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15859641.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


88. Gómez García I, Molina Burgos R, Fernández Fernández E, Palacio España A, González Chamorro F, Alvarez E, Conde Someso S: [Myofibroblastic tumor of bladder]. Actas Urol Esp; 2005 Jun;29(6):611-4
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Myofibroblastic tumor of bladder].
  • [Transliterated title] Tumor miofibroblástico de vejiga.
  • The myofibroblastic tumor, is a mesenchymal benign tumor of exceptional character, being its localization but habitual it is the lung; while its appearance in the bladder, is exceptional, not existing but of 100 published cases, of this tumor type in the bladder.
  • This tumor type that clinic and radiologics, behave as a wicked tumor.
  • We present a new case of this neoplasm, carrying out a wide bibliographical revision.
  • [MeSH-major] Granuloma, Plasma Cell / diagnosis. Urinary Bladder Diseases / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16092689.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


89. Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, Chua CW, Chan KW, Chan FL, Glackin C, Wong YC, Wang X: Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res; 2005 Jun 15;65(12):5153-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using malignant and nonmalignant prostate tissues, we found that TWIST expression was highly expressed in the majority (90%) of prostate cancer tissues but only in a small percentage (6.7%) of benign prostate hyperplasia.
  • Furthermore, down-regulation of TWIST through small interfering RNA in androgen-independent prostate cancer cell lines, DU145 and PC3, resulted in increased sensitivity to the anticancer drug taxol-induced cell death which was associated with decreased Bcl/Bax ratio, leading to activation of the apoptosis pathway.
  • More importantly, inactivation of TWIST suppressed migration and invasion abilities of androgen-independent prostate cancer cells, which was correlated with induction of E-cadherin expression as well as morphologic and molecular changes associated with mesenchymal to epithelial transition.
  • Our results have identified TWIST as a critical regulator of prostate cancer cell growth and suggest a potential therapeutic approach to inhibit the growth and metastasis of androgen-independent prostate cancer through inactivation of the TWIST gene.
  • [MeSH-minor] Apoptosis / drug effects. Apoptosis / physiology. Cell Line, Tumor. Epithelial Cells / pathology. Gene Expression Regulation, Neoplastic. Gene Silencing. Humans. Male. Mesoderm / pathology. Neoplasm Invasiveness. Paclitaxel / pharmacology. Transfection. Twist Transcription Factor. Up-Regulation

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15958559.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / TWIST1 protein, human; 0 / Transcription Factors; 0 / Twist Transcription Factor; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


90. Eversole LR: Cellular angiofibroma of oral mucosa: report of two cases. Head Neck Pathol; 2009 Jun;3(2):136-9
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cellular angiofibroma is a benign vascular neoplasm that typically arises in the vulva, perineal, and paratesticular region.
  • Recent evidence indicates that cellular angiofibromas may be cytogenetically related to spindle cell lipoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sao Paulo Med J. 2005 Sep 1;123(5):250-2 [16358102.001]
  • [Cites] Am J Obstet Gynecol. 2005 Nov;193(5):1750-2 [16260223.001]
  • [Cites] Virchows Arch. 2006 Oct;449(4):489-92 [16957933.001]
  • [Cites] APMIS. 2007 Mar;115(3):254-8 [17367472.001]
  • [Cites] Histopathology. 2007 Sep;51(3):410-2 [17727484.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Sep;177(2):131-4 [17854668.001]
  • [Cites] Pathology. 2008 Apr;40(3):330-3 [18428064.001]
  • [Cites] Histopathology. 2000 Feb;36(2):97-108 [10672053.001]
  • [Cites] Int J Gynecol Pathol. 2001 Apr;20(2):105-27 [11293156.001]
  • [Cites] Int J Gynecol Pathol. 2001 Apr;20(2):200-3 [11293169.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):326-9 [11330972.001]
  • [Cites] J Clin Pathol. 2002 Jun;55(6):477-9 [12037036.001]
  • [Cites] Ann Pathol. 2002 Jun;22(3):241-3 [12410114.001]
  • [Cites] J Cutan Pathol. 2003 Jul;30(6):405-11 [12834491.001]
  • [Cites] Eur J Gynaecol Oncol. 2004;25(2):242-4 [15032293.001]
  • [Cites] Histopathology. 2004 Oct;45(4):360-8 [15469474.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1426-35 [15489646.001]
  • [Cites] Am J Surg Pathol. 1997 Jun;21(6):636-44 [9199640.001]
  • [Cites] Int J Gynecol Pathol. 1997 Oct;16(4):325-34 [9421071.001]
  • [Cites] J Cutan Pathol. 1998 Jul;25(6):327-32 [9694623.001]
  • [Cites] Int J Urol. 2006 Feb;13(2):177-9 [16563146.001]
  • (PMID = 19644547.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Angiofibroma / Hemangioma / Mesenchymal tumor / Oral cavity / Vascular tumor
  •  go-up   go-down


91. Pellegrino M, Vadrucci S, Tinelli A: [Angiomyofibroblastoma of the vulva: a rare but distinct entity. Case report and literature review]. Pathologica; 2007 Dec;99(6):438-9
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiomyofibroblastoma is a benign vulvar tumour involving soft tissue that is characterized by alternating hypocellular and hypercellular areas of spindle stromal cells, admixed and aggregated around blood vessels.
  • It is important to recognize this entity as it shows benign behaviour with respect to other mesenchymal tumours of the vagina, which have a more aggressive behaviour.
  • [MeSH-minor] Adult. Antigens, CD34 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor. Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Combined Modality Therapy. Female. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / surgery. Neoplasm Proteins / analysis. Receptors, Estrogen / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18416337.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen
  • [Number-of-references] 7
  •  go-up   go-down


92. Perez D, Demartines N, Meier K, Clavien PA, Jungbluth A, Jaeger D: Protein S100 as prognostic marker for gastrointestinal stromal tumors: a clinicopathological risk factor analysis. J Invest Surg; 2007 May-Jun;20(3):181-6
Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastrointestinal stromal tumors (GISTs) are a heterogenous group of mesenchymal neoplasms ranging from semibenign tumors to highly aggressive neoplasms.
  • Predicting their clinical behavior is challenging and criteria delineating benign from malignant cases are controversially discussed.
  • In addition we confirmed the previously reported impact of initial tumor size on survival and recurrence rate (p = .034 and p = .039).
  • The series was also analyzed according to established prognostic factors (tumor size and mitotic activity), which indicated that 77% of S100-positive cases were at high risk for malignant tumor behavior, 15% at intermediate risk, and 8% at low risk.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Gastrointestinal Stromal Tumors / metabolism. Gastrointestinal Stromal Tumors / pathology. S100 Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Differentiation. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613693.001).
  • [ISSN] 0894-1939
  • [Journal-full-title] Journal of investigative surgery : the official journal of the Academy of Surgical Research
  • [ISO-abbreviation] J Invest Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


93. He Y, Yang KX, Yang F, Wu XL: Primary solitary fibrous tumor of the vulva: a case report. J Reprod Med; 2010 Sep-Oct;55(9-10):452-6
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary solitary fibrous tumor of the vulva: a case report.
  • BACKGROUND: Solitary fibrous tumor (SFT) of the female genital tract is an extremely rare neoplasm of mesenchymal origin.
  • The tumor presented as a 10-cm, well-circumscribed lump and was composed of bland-looking cells admixed with thin and thick collagen fibers with the appearance of hemangiopericytoma.
  • Microscopic evaluation and immunohistochemistry supported the diagnosis of a primary benign vulvar SFT.
  • SFT should be taken into consideration during the diagnostic process with spindle cell lesions of the vulva.
  • The outcome of this tumor is based mostly on complete surgical resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21043376.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Jundt G, Reichart PA: [Malignant odontogenic tumors]. Pathologe; 2008 May;29(3):205-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As with benign odontogenic tumors, malignant epithelial odontogenic tumors or odontogenic carcinomas are distinguished from the even rarer mesenchymal ones, the odontogenic sarcomas.
  • Odontogenic carcinomas comprise ameloblastic carcinoma (AmCa), primary intraosseous carcinoma (PIOC), clear cell odontogenic carcinoma, odontogenic ghost cell carcinoma (OGCC), and the special case of metastasizing ameloblastoma.
  • [MeSH-minor] Ameloblastoma / classification. Ameloblastoma / pathology. Carcinoma / classification. Carcinoma / pathology. Carcinosarcoma / classification. Carcinosarcoma / pathology. Diagnosis, Differential. Humans. Jaw / pathology. Neoplasm Invasiveness. Sarcoma / classification. Sarcoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Craniomaxillofac Surg. 2005 Oct;33(5):352-5 [16129612.001]
  • [Cites] J Dent Res. 2003 Jul;82(7):551-7 [12821718.001]
  • [Cites] Dentomaxillofac Radiol. 2004 May;33(3):152-7 [15371314.001]
  • [Cites] Int J Oral Maxillofac Surg. 2007 Jan;36(1):20-5 [17156974.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994;30B(2):126-31 [7913362.001]
  • [Cites] Pathol Res Pract. 1979 Dec;166(1):123-30 [551398.001]
  • [Cites] J Oral Pathol Med. 1998 Feb;27(2):59-63 [9526730.001]
  • [Cites] Int J Oral Maxillofac Surg. 2001 Aug;30(4):349-55 [11518362.001]
  • [Cites] J Oral Pathol Med. 2005 May;34(5):318-20 [15817077.001]
  • [Cites] J Craniofac Surg. 2003 May;14(3):356-62 [12826807.001]
  • [Cites] Dtsch Z Mund Kiefer Gesichtschir. 1991 Mar-Apr;15(2):90-3 [1816940.001]
  • [Cites] Pathol Res Pract. 1983 Aug;178(1):40-7 [6227872.001]
  • [Cites] Hua Xi Yi Ke Da Xue Xue Bao. 1998 Dec;29(4):390-3 [10743235.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jun;103(6):799-807 [17448710.001]
  • [Cites] Rev Stomatol Chir Maxillofac. 2003 Oct;104(5):265-73 [14679345.001]
  • [Cites] Pathol Res Pract. 1985 Nov;180(5):526-35 [4080638.001]
  • [Cites] J Oral Maxillofac Surg. 2003 May;61(5):580-6 [12730837.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Apr;65(4):777-83 [17368379.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Feb;61(2):256-8 [12619007.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jul;104(1):72-5 [17577546.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Apr;103(4):516-20 [17395065.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Sep;65(9):1820-4 [17719405.001]
  • [Cites] Arch Pathol Lab Med. 1993 Nov;117(11):1126-31 [8239934.001]
  • [Cites] Mod Pathol. 2004 Sep;17 (9):1062-7 [15133474.001]
  • [Cites] Head Neck. 2005 Jun;27(6):536-42 [15772956.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Feb;101(2):194-200 [16448921.001]
  • [Cites] J Craniofac Surg. 2004 Mar;15(2):264-9 [15167247.001]
  • [Cites] Virchows Arch. 2001 Apr;438(4):412-7 [11355179.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1977 Mar;43(3):391-401 [265043.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Jun;121(6):685-9 [7772324.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jan;103(1):72-6 [17178497.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Aug;88(2):170-6 [10468461.001]
  • [Cites] J Oral Pathol Med. 1989 Feb;18(2):113-8 [2746520.001]
  • [Cites] Med Oral. 2001 May-Jul;6(3):173-9 [11500634.001]
  • (PMID = 18392827.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


95. Chen E, Fletcher CD: Cellular angiofibroma with atypia or sarcomatous transformation: clinicopathologic analysis of 13 cases. Am J Surg Pathol; 2010 May;34(5):707-14
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cellular angiofibroma is a mesenchymal neoplasm that is characterized by a bland spindle cell component, morphologically reminiscent of spindle cell lipoma, and thick-walled vessels.
  • The tumor occurs equally in men and women and usually arises in the inguino-scrotal or vulvovaginal regions.
  • An earlier study of 51 cases from our group showed that the tumor follows a benign course without any tendency for recurrence.
  • Tumor size ranged from 1.2 to 7.5 cm.
  • Most tumors were located in subcutaneous tissue.
  • Three of these 9 cases showed discrete nodule(s) closely resembling atypical lipomatous tumor within usual cellular angiofibroma.
  • The 3 cases with atypical lipomatous tumor-like areas were negative for MDM-2 and CDK4.
  • Cellular angiofibroma with atypia or morphologic sarcomatous transformation occurs predominantly in the subcutaneous tissue of the vulva and, as yet, shows no evident tendency to recur based on limited clinical follow-up available for 7 cases.
  • The sarcomatous component can show variable features including atypical lipomatous tumor, pleomorphic liposarcoma, and pleomorphic sarcoma NOS.
  • [MeSH-major] Angiofibroma / pathology. Cell Transformation, Neoplastic. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Female. Humans. Male. Middle Aged. Vulva / pathology. Vulvar Neoplasms / chemistry. Vulvar Neoplasms / pathology. Vulvar Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305534.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


96. Berrebi O, Steiner C, Keller A, Rougemont AL, Ratib O: F-18 fluorodeoxyglucose (FDG) PET in the diagnosis of malignant transformation of fibrous dysplasia in the pelvic bones. Clin Nucl Med; 2008 Jul;33(7):469-71
Genetic Alliance. consumer health - Fibrous Dysplasia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibrous dysplasia (FD) is a benign dysplastic pathology of bone-forming mesenchymal cells, resulting in replacement of trabecular bone by abnormal fibrous and immature osseous tissue.
  • We report the case of a 59-year-old woman with monostotic FD of the left ischium, known for over 30 years, who developed sarcomatous transformation in a low-grade spindle-cell sarcoma.
  • [MeSH-major] Fibrous Dysplasia of Bone / diagnosis. Fibrous Dysplasia of Bone / radionuclide imaging. Fluorodeoxyglucose F18. Pelvis / radionuclide imaging. Radiopharmaceuticals
  • [MeSH-minor] Bone and Bones / radionuclide imaging. Cell Proliferation. Cell Transformation, Neoplastic. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Metastasis. Positron-Emission Tomography / methods. Sarcoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580231.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Databank-accession-numbers] OMIM/ 174800
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


97. Salem F, Rosenblum MK, Jhanwar SC, Kancherla P, Ghossein RA, Carlson DL: Teratocarcinosarcoma of the nasal cavity and paranasal sinuses: report of 3 cases with assessment for chromosome 12p status. Hum Pathol; 2008 Apr;39(4):605-9
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sinonasal teratocarcinosarcoma (SNTCS) is a rare malignant neoplasm with 63 reported cases to date.
  • Histologically, these tumors are characterized by the presence of admixed epithelial and mesenchymal components.
  • Two SNTCSs from the archives of Memorial Sloan-Kettering Cancer Center and one submitted from St Luke's-Roosevelt Hospital Center were evaluated by fluorescent in situ hybridization for amplification of chromosome12p, an event usually associated with the genesis of bona fide germ cell neoplasms (including mediastinal and testicular teratomas).
  • Microscopic examination revealed admixed epithelial and mesenchymal elements in all 3 cases; benign squamous and glandular epithelium and neuroepithelial tissue were identified, the squamous epithelium demonstrating "fetal-like" cytoplasmic clearing.
  • Mesenchymal proliferations were recognized ranging from well-differentiated smooth muscle to high-grade sarcoma.
  • A malignant germ cell component was not identified in any of the cases.
  • Our findings suggest that 12p amplification, if it occurs at all in this setting, is exceptional and that SNTCS is a somatic-type neoplasm exhibiting divergent differentiation rather than a germ cell tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18284932.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement